

8-23-2019

## Mechanisms of simvastatin myotoxicity: The role of autophagy flux inhibition.


Arya Emami  
*University of Manitoba*

Shahla Shojaei  
*University of Manitoba*

Simone C. da Silva Rosa  
*University of Manitoba; Children's Hospital Research Institute of Manitoba*

Mahmoud Aghaei  
*University of Manitoba; Isfahan University of Medical Sciences*

Ehsan Samiei  
Follow this and additional works at: <https://jdc.jefferson.edu/transmedfp>  
*University of Victoria*

 Part of the [Cardiology Commons](#), [Other Pharmacology, Toxicology and Environmental Health Commons](#), [Pulmonology Commons](#), and the [Translational Medical Research Commons](#)

*See next page for additional authors*

**[Let us know how access to this document benefits you](#)**

### Recommended Citation

Emami, Arya; Shojaei, Shahla; da Silva Rosa, Simone C.; Aghaei, Mahmoud; Samiei, Ehsan; Vosoughi, Amir Reza; Kalantari, Forouh; Kawalec, Philip; Thliveris, James; Sharma, Pawan; Zeki, Amir A.; Akbari, Mohsen; Gordon, Joseph W.; and Ghavami, Saeid, "Mechanisms of simvastatin myotoxicity: The role of autophagy flux inhibition." (2019). *Center for Translational Medicine Faculty Papers*. Paper 63.  
<https://jdc.jefferson.edu/transmedfp/63>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Center for Translational Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

## Authors

Arya Emami, Shahla Shojaei, Simone C. da Silva Rosa, Mahmoud Aghaei, Ehsan Samiei, Amir Reza Vosoughi, Forouh Kalantari, Philip Kawalec, James Thliveris, Pawan Sharma, Amir A. Zeki, Mohsen Akbari, Joseph W. Gordon, and Saeid Ghavami

# Mechanisms of Simvastatin Myotoxicity: The Role of Autophagy Flux Inhibition

*Running Title: Autophagy Flux and Myotoxicity*

<sup>1</sup>¥Arya Emami, <sup>1</sup>¥Shahla Shojaei, <sup>1,2</sup>¥Simone C da Silva Rosa, <sup>1,3</sup>Mahmoud Aghaei, <sup>4</sup>Ehsan Samiei, <sup>1</sup>Amir Reza Vosoughi, <sup>1</sup>Forouh Kalantari, <sup>1</sup>Philip Kawalec, <sup>1</sup>James Thliveris, <sup>5</sup>Pawan Sharma, <sup>6, 7, 8</sup>Amir A Zeki, <sup>4</sup>Mohsen Akbari, <sup>\*1,2,12</sup>Joseph W. Gordon, <sup>\*1,8, 9, 10</sup>Saeid Ghavami

<sup>1</sup>Department of Human Anatomy & Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

<sup>2</sup>Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.

<sup>3</sup>Department of Clinical Biochemistry, School of Pharmacy & Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

<sup>4</sup>Laboratory for Innovations in Microengineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC V8P 5C2, Canada; Centre for Advanced Materials and Related Technologies (CAMTEC), University of Victoria, Victoria, BC, V8P 5C2, Canada; Centre for Biomedical Research (CBR), University of Victoria, Victoria, BC, V8P 5C2, Canada.

<sup>5</sup>Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA USA 19107.

<sup>6</sup>University of California, Davis. Department of Internal Medicine. Division of Pulmonary, Critical Care, and Sleep Medicine, Sacramento, CA.

<sup>7</sup> Veterans Affairs Medical Center, Mather, CA.

<sup>8</sup> Center for Comparative Respiratory Biology and Medicine, Davis, CA.

<sup>9</sup>Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.

<sup>10</sup>Research Institute of Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, Canada.

<sup>11</sup>Autophagy Research Center, Health Policy Research Centre, Shiraz University of Medical Science, Shiraz, Iran.

<sup>12</sup>College of Nursing, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

\*These authors have senior authorship

¥ These authors have equal first authorship

Address for Correspondence: Saeid Ghavami, Department of Human Anatomy & Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. Email: [saeid.ghavami@umanitoba.ca](mailto:saeid.ghavami@umanitoba.ca)

Key words: statin, autophagy flux, prenylation, 3D culture mode

## Abstract

Statins are some of the most widely used drugs worldwide, but one of their major side effects is myotoxicity. Using mouse myoblast (C2C12) and human alveolar rhabdomyosarcoma cell lines (RH30) in 2-dimensional (2D) and 3-dimensional (3D) culture, we investigated the mechanisms of simvastatin's myotoxicity. We found that simvastatin significantly reduced cell viability in C2C12 cells compared to RH30 cells. However, simvastatin induced greater apoptosis in RH30 compared to C2C12 cells. Simvastatin-induced cell death is dependent on Geranylgeranyl pyrophosphate (GGPP) in C2C12 cells, while in RH30 cells it is dependent on both Farnesyl pyrophosphate (FPP) and GGPP. Simvastatin inhibited autophagy flux in both C2C12 and RH30 cells and inhibited lysosomal acidification in C2C12 cells, while autophagy inhibition with Bafilomycin-A1 increased simvastatin myotoxicity in both cell lines. Simvastatin induced more cell death in RH30 cells compared to C2C12 in 3D culture model with similar effects on autophagy flux as in 2D culture. Overall our results suggest that simvastatin-induced myotoxicity involves both apoptosis and autophagy, where autophagy serves a pro-survival role in both cell lines. The sensitivity to simvastatin myotoxicity is different in 2D versus 3D culture, demonstrating that the cellular microenvironment is a critical factor in regulating simvastatin-induced cell death in myoblasts.

## INTRODUCTION

The statin drugs ('statins') are competitive inhibitors of HMG-CoA (3-hydroxy-3-methylglutarylcoenzyme A) reductase, and thus attenuate cholesterol and isoprenoid biosynthesis in the mevalonate (MA) pathway (Endo et al., 1977). They are used clinically as lipid-lowering drugs that prevent and treat cardiovascular diseases including atherosclerosis, coronary artery disease, and stroke (Grundy and Vega, 1985; Illingworth and Sexton, 1984; Tikkanen and Nikkila, 1987). The MA pathway is an essential contributor to mammalian cell homeostasis, as it is involved in the regulation of a multitude of cellular processes that require cholesterol and the isoprenoid intermediates (Cartocci et al., 2017; Hashemi et al., 2017). Cholesterol is the final sterol product of the MA cascade but several upstream isoprenoid metabolites including Farnesyl pyrophosphate (FPP) and Geranylgeranyl pyrophosphate (GGPP) are necessary for the prenylation of monomeric small GTPase proteins (e.g. Rho, Ras, Rac, Cdc42, Rab, Rap) (Hashemi et al., 2017; Sheikholeslami et al., 2019). These prenylated GTPases are critical cell signaling molecules involved in many basic cellular processes including proliferation, growth, migration, cytoskeletal dynamics, vesicular trafficking, barrier integrity, and smooth muscle contraction, to name a few. Thus, the MA pathway is tightly regulated to maintain these precise cellular functions under varied conditions in many cell types critical to health and disease (Jiao et al., 2017; Yeganeh et al., 2014).

Statins are generally well-tolerated medications, however, there are side effects associated with these compounds which are dose-dependent. One of the most important and clinically relevant side effects is skeletal muscle myopathy which occurs in 1–5% of patients who take statins. Rarely, this can lead to lethal rhabdomyolysis if it is not diagnosed promptly (Ballantyne et al., 2003; Graham et al., 2004; Staffa et al., 2002; Thompson et al., 2003). According to recent

investigations, statin-related muscle disorders are potentially dependent on the inhibition of FPP and GGPP (Bhardwaj et al., 2013; Matzno et al., 1997). Treatment of C2C12 cells with GGPP can reverse the inhibitory effects of statins on myotube formation (Baba et al., 2008). In support of these findings, there is evidence that statin-induced muscle toxicity is connected to the inhibition of protein geranylgeranylation (Johnson et al., 2004), where prenylation of small GTPases is essential to their signaling function, including RAP GTPase. This reaction exclusively requires geranylgeranylation of RAP1A small Rho-GTPase protein, which is catalyzed by the prenyltransferases (Crick et al., 1997). Although these investigations have been illuminating regarding statin-induced muscle toxicity, the exact mechanisms underlying this phenomenon remain incompletely understood.

Macroautophagy (hereafter listed as autophagy) is a multi step “self-eating” physiological process that regulates cellular response to stress (Amiri et al., 2019). Autophagy can be involved in both survival and death mechanisms based on the type of the cells and stimuli (Hombach-Klonisch et al., 2018; Mokarram et al., 2017). Once it has been induced, tightly regulated sequential steps direct the formation of a bilayer vesicle called the autophagosome to consume cytoplasmic cargo (Klionsky et al., 2016; Mehrbod et al., 2019). This cargo is then ubiquitinated and recognized by autophagy receptors like p62. The cargo receptor later binds to the cargo and LC3-II, a component of the autophagosome membrane, which facilitates the isolation of the cargo and its delivery to lysosomes.

Autophagy can be involved in regulation of programmed cell death I (apoptosis) under different scenarios: i) as a positive controller (autophagy increases apoptosis), ii) as a negative controller (autophagy decreases apoptosis), or iii) parallel to apoptosis (autophagy does not change cellular apoptosis) (Ghavami et al., 2010a; Ghavami et al., 2010b; Ghavami et al., 2012a;

Ghavami et al., 2011; Ghavami et al., 2014; Ghavami et al., 2012b; Liu et al., 2017; Song et al., 2017). Investigators have used autophagy and apoptosis cross regulation to develop new therapeutic approaches for cancer. For example, different autophagy inducers and inhibitors have been used with chemotherapy agents, and radiotherapy to increase the efficiency of cancer therapy in some patients (Hombach-Klonisch et al., 2018; Mokarram et al., 2017).

We have previously studied cell death mechanisms of statins in airway smooth muscle and recently established a research program in developing new therapeutic approaches for Rhabdomyosarcoma (RMS). Previous investigations have used C2C12 mouse myoblasts (Jaskiewicz et al., 2019; Schirris et al., 2015a) as a model for investigation of statins myopathy. In the current study, we aim to understand the myotoxic effects of statins, using the rhabdomyosarcoma cell line (RH30) (Moghadam et al., 2018) as well as C2C12 cell lines to address this clinically relevant question.

## **MATERIALS and METHODS**

### *Chemicals and Antibodies*

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (M2128), simvastatin (S6196), FPP (F6892), GGPP (G6025), cholesterol (47129), mevalonate (68519), LC3 $\beta$  antibody (L7543), and beta actin antibody (A2228) were purchased from Sigma/Aldrich (Canada, Ontario). Dimethyl sulfoxide (DMSO) (4948-02) were purchased from VWR (Canada, Ontario). SQSTM1/p62 antibody (5114) were purchased from cell singling (Canada Ontario). Cleaved PARP (Asp214) (D64E10) XP $\text{\textcircled{R}}$  Rabbit mAb, LC3B (D11) XP $\text{\textcircled{R}}$  Rabbit mAb, and SQSTM1/p62 (D5L7G) Mouse mAb were purchased from Cell Signaling Technology. Alexa Fluor $\text{\textcircled{R}}$  488 AffiniPure Donkey Anti-Rabbit IgG, and Alexa Fluor $\text{\textcircled{R}}$  647 AffiniPure Donkey Anti-Mouse IgG secondary antibodies and IgG-free bovine serum albumin (BSA) were purchased from Jackson ImmunoResearch Inc. DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) was purchased from Thermo Fisher Scientific. Bovine type 1 collagen (10 mg/mL) was purchased from Advanced BioMatrix Inc. Live/dead viability staining kit was purchased from Millipore Sigma.

### *Cell Lines and Cell Culture*

The human rhabdomyosarcoma cell line (RH30) [RC13, RMS 13, SJRH30] (ATCC $\text{\textcircled{R}}$  CRL-2061 $\text{\textsuperscript{TM}}$ ) (Human muscle cancer cells) and mouse muscle cell line (C2C12) (ATCC $\text{\textcircled{R}}$  CRL-1772 $\text{\textsuperscript{TM}}$ ) were used in this project. Cells were cultured in Roswell Park Memorial Institute (RPMI- 1640) with L-glutamine and 25mM HEPES (BioWhittaker; Cat #: 12-115Q) and Dulbecco's Modified Eagle's Medium (DMEM) (CORNING; Cat #: 50-003-PB) with 10% fetal bovine serum (FBS) (Gibco $\text{\textsuperscript{TM}}$ ; Cat #: 16000044). RH30 cell lines were cultured in RPMI-1640 with L-glutamine and 25 mM HEPES media, and C2C12 cells were cultured in DMEM with high glucose media. Both media were supplemented with FBS (10%), penicillin (1%), and



streptomycin (1%). Cells were grown to 35–40% confluency on a 100 mm cell culture plate, 6-well plates, and 96-well plates. Cells were maintained in a humidified incubator with 95% air and 5% CO<sub>2</sub> at 37 °C and were passed once every 2–3 days. Cell culture plastic ware, penicillin, and streptomycin were purchased from VWR (Toronto, ON, Canada).

#### *MTT Assay*

The MTT assay was performed based on a protocol established in our group (Alizadeh et al., 2017; Ghavami et al., 2004; Ghavami et al., 2010b; Ghavami et al., 2012a; Ghavami et al., 2011; Ghavami et al., 2014). Briefly C2C12 (20,000 cells/mL) and RH30 (30,000 cells/mL) were seeded in 96-well plates and treated with varying concentrations of simvastatin (Simva, 0-20 µM). At each time-point (24, 48, 72, and 96 hrs), 20 µL of (MTT, 5 mg/ml) was added to each well. The cells were incubated at 37°C for 4 hours, after which the media was gently aspirated. Then, 200 µL of DMSO was added to each well and mixed with the cells by pipetting to dissolve the MTT formazan crystals. Lastly, the plates were incubated for 20 min at room temperature. Absorbance was measured at 570 nm using a Synergy H1 Microplate Reader.

#### *Mevalonate Cascade Rescue Assay*

Rescue experiments were done according to previously reported protocols (Alizadeh et al., 2017; Ghavami et al., 2012a; Ghavami et al., 2011; Ghavami et al., 2014). Briefly, cells were seeded and grown in 96-well plates at a density of 2,000 cells per well, up to 50% confluence. Cells were pre-treated with 5 mM mevalonate (MeV), 30 µM FPP, 30 µM GGPP, and 50 µM cholesterol, and were incubated at 37°C for 4 hrs. These cells were then co-treated

with 10  $\mu$ M Simvastatin and incubated at 37°C for 96 hrs. Cell viability was then measured using the MTT assay after 96 hrs, as described in the previous section.

### *Immunoblotting*

Western blotting analysis of C2C12 and RH30 cell lysates was used to assess markers of autophagy (LC3 (1:2500), p62 (1:1000)) as has been described in our previous studies (Ghavami et al., 2010b; Ghavami et al., 2012a; Ghavami et al., 2011; Ghavami et al., 2014). Cells were grown to 40-50% confluency in 100 mm dishes and either treated with 10  $\mu$ M Simva or with a drug vehicle control (DMSO). At the appropriate time point, cells were collected, and protein extracts were made using NP-40 Lysis Buffer (0.5% (v/v) Nonidet P-40, 20 mM Tris-HCl (pH 7.5), 0.5% (v/v) PMSF, 100  $\mu$ M  $\beta$ -glycerol 3-phosphate and 1.5% (v/v) protease inhibitor cocktail). Once the protein concentration was known, samples were prepared for western blotting with a total protein concentration of 1  $\mu$ g/ $\mu$ L (15  $\mu$ L of each sample was used). After electrophoresis, the membranes were developed for LC3 $\beta$  and p62 proteins.

### *Measurement of Apoptosis with Flow Cytometry*

We measured apoptosis using the Nicoletti method. C2C12 and RH30 cells were cultured in 6-well plates and treated with either Simva (5 or 10  $\mu$ M) or with a drug vehicle control (DMSO) for 48 hrs. After drug treatment, cells were detached using EDTA buffer and centrifuged at 1,500~~x~~g for 5 min at 4°C. Cells were washed with cold PBS before they were permeabilized and stained with a hypotonic Propidium Iodide (PI) buffer (0.1% Triton X-100, 1% sodium citrate, 0.5 mg/ml RNase A, 40  $\mu$ g/ml propidium iodide). Samples were then incubated for 1 hour in the dark at 4°C to prevent photo-bleaching. Flow cytometry was carried

out at 460 nm for 10,000 cells. Residual debris were gated out accurately to obtain accurate data. The resulting histogram was analyzed to determine the percentage of normal and apoptotic nuclei; the nuclei of apoptotic cells were located on the left side of the G1 peak as they have less DNA compared to the nuclei of healthy G0/G1 cells. For each sample, the sub-G1 peak was measured and statistically compared with other samples to determine significance (Hashemi et al., 2007; Moghadam et al., 2018).

### *Live Cell Imaging*

LC3 is a specific marker for autophagosomes, which are key structures in the process of autophagy. LC3-GFP is a fusion of green fluorescent protein (GFP) and LC3, and it can behave in the same manner as endogenous LC3. LC3-GFP is localized on the autophagosome membrane and emits green light when excited. In a normal cell, LC3 is dispersed evenly through the cytosol. However, when autophagic flux is initiated, LC3 is recruited to autophagosome membranes, resulting in sharp green puncta and LC3-GFP-containing cells. To confirm autophagy findings seen in western blots, C2C12 or RH30 cells were grown in 6-well plates and transfected with a plasmid containing LC3-GFP (Addgene #24920) using Qiagen's Effectene reagent, as per manufacturer's instructions. After transfecting cells for 18 hrs, the cells were treated with either Simva (10  $\mu$ M), Bafilomycin-A1 (Baf-A1, 100 nM), Simva + Baf-A1, or a vehicle control (DMSO). After 24 hrs, the cells were incubated with LysoTracker red dye (Molecular Probes; LysoTracker Red DND-99; L7528) at a concentration of 50 nM to detect lysosomal activity and counterstained with Hoechst. Cells were stained for 30 min in a 37°C incubator. After the 30 min period, the cells were washed with PBS and fresh media was added. The cells were imaged on an epifluorescence microscope. Images were analyzed to determine the

percentage of cells with distinct LC3-GFP puncta and to see if green and red puncta co-localization had occurred, which was assumed to signify the fusion of autophagosomes with lysosomes (Field et al., 2018; Moghadam et al., 2018).

### *Transmission Electron Microscopy (TEM)*

TEM was used to evaluate autophagy in both C2C12 and RH30 cell lines. The TEM protocol is the same as previously described<sup>1</sup>. Briefly, cells were grown in 10 mm dishes (300,000 cells/dish) and treated with either DMSO (drug vehicle control) or 10  $\mu$ M Simva for 48 hrs. At the time point, cells were detached with EDTA and centrifuged at 1,500 $\times$ g. The samples were then fixed with 3% glutaraldehyde in PBS (pH 7.4) for 3 hrs at room temperature. The samples were later treated post-fixation with 1% osmium tetroxide in PBS for 2 hrs, followed by an alcohol dehydration series, and then embedded in Epon and stained with uranyl acetate. They were counterstained with lead citrate for 3 min sequentially and finally washed with water for 1 min and dried. The samples were imaged on a Philips CM10 at 80kV on ultra thin sections (100nm on 200 mesh grids) (Alizadeh et al., 2018a; Moghadam et al., 2018).

### *Culturing C2C12 and RH30 cells in 3D cultures*

C2C12 and RH30 cells were grown in 3D culture according to the same protocol explained in previous publications (Moghadam et al., 2018). Briefly, cells were grown in culture medium (DMEM or RPMI with 10% FBS and 0.5% Pen-Strep) until they reached 80% confluency. Cells were detached with Trypsin-EDTA, spun down, and re-suspended in fresh media. Collagen and media were gently added to the cell suspension at 4°C to reach a final collagen concentration of 3 mg/mL and a cell density of 2 million cells/mL. Then, 20  $\mu$ L of this

solution was added to cylindrical wells with 5 mm diameter and 1 mm depth in PDMS holders which were placed in 12 well-plates and put in a 37°C incubator for 45 min to cure the collagen. Afterwards, 2 mL of media was added to each well and they were incubated overnight. The next day, cells were treated with either DMSO or Simva (Moghadam et al., 2018).

#### *Live-Dead Assay in 3D Culture*

Cells were grown and treated as explained above. Live-dead assay solution was prepared as per the supplier's instructions, where 5 µL of calcein and 20 µL of ethidium homodimer-1 were added to 10 mL of DPBS. After treatment, media was removed, and the live-dead solution was added to the wells. After incubating for 2 hrs at room temperature in the dark, the solution was removed and the cells were gently rinsed with DPBS three times, each time with 5 min incubation. Stained cells were then imaged on a confocal microscope and quantified (Moghadam et al., 2018).

#### *Immunofluorescence (IF) in 3D Culture*

IF was used to confirm apoptosis and autophagy findings by evaluating cleaved-PARP, LC3, and p62 levels. C2C12 and RH30 cells were treated with DMSO or 10 µM Simva for 96 or 48 hrs, respectively. At the appropriate time point, media was removed, and cells were fixed by incubating them with 4% paraformaldehyde in PBS for 15 min at room temperature. Paraformaldehyde was then removed, and cells were washed 3 times with PBS. Cells were blocked with blocking buffer (5% goat serum, 0.3% Triton-X in RBS) at room temperature. After 60 to 120 min, blocking buffer was removed and the appropriate primary antibody—p62, LC3, or c-PARP—was diluted 1:300 in Antibody Buffer (1% BSA, 0.3% Triton-X in PBS) and

incubated with the samples overnight at 4°C. The next day, the antibody solution was removed, and cells were washed three times with PBS. Cells were then incubated with the appropriate fluoro-conjugated secondary antibody which was diluted 1:400 in Antibody Buffer. Samples were incubated in the dark for 2 hrs at room temperature, and then washed with PBS. Finally, the cells were incubated with DAPI solution for 1 hr in the dark. After washing three times with PBS, cells were immediately taken for imaging (Moghadam et al., 2018).

### *Statistical Analysis*

All results were presented as mean  $\pm$  SD, and the differences between the groups were tested by one-way ANOVA or two-way ANOVA analysis (non-parametric, Brown–Forsythe test), using GraphPad Prism 7.0. The confidence interval in each analysis was 95%, and  $p < 0.05$  was considered statistically significant.

## **RESULTS**

### *Mevalonate Cascade Inhibition Induces Cell Death in Both RH30 and C2C12 Cells*

We previously showed that the MA cascade inhibitor simvastatin induces cell death in a broad range of primary cells (primary airway mesenchymal cells, and primary atrial fibroblasts) (Ghavami et al., 2010b; Ghavami et al., 2011; Ghavami et al., 2014) and tumor cell lines

(Alizadeh et al., 2018b; Alizadeh et al., 2017; Sheikholeslami et al., 2019) including breast (MCF-7, MDA-MB231), brain (U87, U251), and lung (A549, H1965), as well as medulloblastoma brain tumor cell lines (Daoy, D283, and D341 cells). Lovastatin and mevalonate cascade inhibitors (GGTi-298, 6-Fluoromevalonate) also inhibit ovarian cancer tumor growth (Kobayashi et al., 2017; Kobayashi et al., 2015).

We now demonstrate that simvastatin induces dose- (0-20  $\mu$ M) and time- (0-96 hr) dependent cell death in both RH30 (Fig. 1 A-D) and C2C12 cells (Fig. 1 E-H). In RH30 cells, simvastatin (20  $\mu$ M) significantly induced cell death ( $p < 0.05$ ) in 24 hrs (Fig. 1 A), simvastatin (10, 20  $\mu$ M) significantly induced cell death ( $p < 0.0001$ ) in 48 hrs (Fig. 1 B), simvastatin (5,10, 20  $\mu$ M) significantly induced cell death ( $p < 0.05$ ,  $p < 0.0001$ ) in 72 and 96 hrs (Fig. 1 C&D). Interestingly, simvastatin (0.5-20  $\mu$ M) induced significant cell death ( $p < 0.001$ ,  $p < 0.0001$ ) in all time points (24-96 hr) in C2C12 cells (Fig.1 E-H). The morphology of RH30 cells treated with simvastatin (10  $\mu$ M) is shown in Fig. 1J and compared with RH30 time-matched control. Simvastatin at concentrations of  $\geq 2.5$   $\mu$ M induced significant cell death in C2C12 cells as compared to RH30 cells ( $p < 0.01$ ).

#### *Prenylation Precursors Differentially Control Simvastatin-Induced Cell Death in C2C12 and RH30 Cells.*

We know that mevalonate (MEV) can reverse statin-induced cell death in many cell models, and GGPP is the major regulator of prenylation events among the isoprenoid intermediates. We now show that MA (5 mM) significantly ( $p < 0.0001$ ) inhibits simvastatin- (10  $\mu$ M) induced cell death in both C2C12 (Fig. 2 A) and RH30 (Fig. 2E) cells. While GGPP (30

μM) significantly ( $p < 0.0001$ ) inhibited simvastatin-induced cell death in both C2C12 (Fig. 2B) and RH30 (Fig. 2F) cells, it was more effective in rescuing RH30 cells than C2C12 cells (Fig. 2J). We found that FPP (30 μM) did not significantly inhibit simvastatin-induced cell death in C2C12 cells (Fig. 2C), but it did significantly ( $p < 0.01$ ) inhibit simvastatin-induced cell death in RH30 cells (Fig. 2G). FPP was also more effective in rescuing RH30 cells against simvastatin-induced cell death (Fig. 2K). Furthermore, cholesterol (50 μM) did not significantly inhibit simvastatin-induced cell death in either C2C12 (Fig. 2D) or RH30 (Fig. 2I).

### *Mevalonate Cascade Inhibition Induces Apoptosis in Both C2C12 and RH30 Cells*

Mevalonate cascade inhibition can induce apoptosis in many cell models (Alizadeh et al., 2018b; Alizadeh et al., 2017; Ghavami et al., 2010b; Ghavami et al., 2012b). In this study, we show that simvastatin induces dose- (5, 10 μM) and time-dependent (48, 72 hr) apoptosis in both C2C12 (Fig. 3A-C) and RH30 (Fig. 3D-F) cells ( $p < 0.01$ ,  $p < 0.0001$ ). We also show that simvastatin significantly induces greater apoptosis in RH30 cells as compared to C2C12 cells (Fig. 3G) ( $p < 0.01$ ).

### *Mevalonate Cascade Inhibition Induces Blockage of Autophagy Flux in Both C2C12 and RH30 Cells While Inhibiting the Acidification of Lysosomes in C2C12 Cells*

Statins can induce autophagy in different types of cells (Ghavami et al., 2011; Ghavami et al., 2014; Ghavami et al., 2012b). Our current study shows that statins inhibit autophagy flux in both RH30 and C2C12 cells. We show that simvastatin (10 μM) increases LC3 lipidation and induced p62 accumulation in both RH30 and C2C12 cells (Fig. 4A). To further confirm our results, using GFP-LC3 and lysotracker immunostaining, we show that simvastatin induced



significant increase of LC3 puncta in both C2C12 and RH30 (Fig. 4B-D) while in C2C12 cells prevented acidification of lysosomes (Fig. 4B) (lack of lysotracker red activity in simvastatin-treated cells). We further confirmed our results using the autophagy inhibitor Bafilomycin A1 (Baf-A1, 100 nM for 1 hr) and show that adding Baf-A1 does not significantly increase the number of LC3 puncta in both C2C12 (Fig. 4 E&G) and RH30 cells (Fig 4 F&H). We also confirmed increased numbers of autophagosomes in both C2C12 (Fig. 4I) and RH30 cells (Fig 4J). We then used Baf-A1 (4 nM) in presence and absence of simvastatin (10  $\mu$ M, 24 hrs) in C2C12 and RH30 cells (Fig 4K). Immunoblotting results confirmed further inhibition of autophagy flux in both C2C12 and RH30 cells (increase of LC3 $\beta$  lipidation and decrease of p62 degradation) (Fig 4K). Further, inhibition of autophagy significantly increased simvastatin-induced myotoxicity in both C2C12 and RH30 cells (Fig 4L&M).

### *Simvastatin Induces Apoptotic Cell Death and Inhibits Autophagy in Both C2C12 and RH30 Cells in 3D Culture*

Cells cultured in 3D configurations using hydrogel biomaterials display a more physiologically-relevant phenotype (Seyfoori et al., 2018). We recently showed that 3D-cultured C2C12 and RH30 cells can be used to screen drugs (Moghadam et al., 2018). In this study, we used this same 3D technique to evaluate the effect of simvastatin on C2C12 and RH30 cells. We performed live/dead assays in 3D culture of C2C12 and RH30 cells and show that simvastatin (5, 10  $\mu$ M) induces both dose- and time- (48, 96 hrs) dependent cell death (Fig. 5 A-H). Also, simvastatin induced significant ( $p < 0.0001$ ) cell death in both C2C12 (Fig. 5 A, C, E&F) and RH30 (Fig. 5 B, D, G, H) cells in the 3D model. However, when cultured in the 3D hydrogel,

simvastatin induced more cell death in RH30 cells as compared to C2C12 cells. This was opposite to the effect we observed when such cells were culture in standard 2D conditions. In addition, simvastatin (10  $\mu$ M) induces apoptotic cell death in both C2C12 and RH30 cells (cleavage of PARP) in the 3D culture model (Fig. 5 I, J). We further investigated the effects of simvastatin on autophagy in both C2C12 and RH30 3D culture cells. We showed that simvastatin inhibits autophagy flux in 3D culture model (increase of LC3 puncta and lack of localization with p62) in both C2C12 and RH30 cells (Fig. 5 K&L).

## DISCUSSION

Our previous studies have demonstrated that the HMG-CoA reductase inhibitor simvastatin induces endoplasmic reticulum stress/unfolded protein response, autophagy, and apoptosis in human airway smooth muscle (HASM) cells, human airway fibroblasts (HAF), and human atrial fibroblasts through inhibition of GGPP biosynthesis (Ghavami et al., 2012a; Ghavami et al., 2011; Ghavami et al., 2014). Previously, we also showed that simvastatin induces apoptotic cell death in a wide variety of tumor cells (lung, brain, and breast) via inhibition of geranylgeranylation of small Rho GTPases (Alizadeh et al., 2017) .

Statin-induced myotoxicity is a major concern for clinicians and basic scientists alike, and several recent investigations have focused on the possible underlying mechanisms involved in statin myotoxicity. In the current investigation, we used C2C12 as our non-cancerous cell line and RH30 as a cancer skeletal muscle cell line to elucidate the mechanisms underlying simvastatin-induced myotoxicity. Our experiments utilized both monolayer 2D and 3D cell culture models, which are more physiologically relevant accounting in part for the cellular microenvironment.

Previous investigations have demonstrated that statin-induced myotoxicity occurs via vacuolation of skeletal muscle fibers, blebbing of sarcolemma, and cell necrosis (Sakamoto et al., 2007). Inhibition of the mitochondrial complex III is involved in statin-induced myotoxicity in C2C12 cells (Schirris et al., 2015b). Other reports indicated that mitochondria (Bouitbir et al., 2012; Kwak et al., 2012; Schirris et al., 2015b),  $\text{Ca}^{2+}$  homeostasis (Sirvent et al., 2012), plasma membrane mono-carboxylate transporter (Kobayashi et al., 2006), plasma membrane receptors (Dricu et al., 1997; Siddals et al., 2004), and ubiquitin ligases (Cao et al., 2009) are statins' primary targets for myotoxicity. Here we show that simvastatin induced cell death in both C2C12 and RH30 cells. However, there were significant differences between C2C12 and RH30 in cell viability (MTT assay) after treatment with simvastatin in 2D monolayer cell culture (simvastatin caused significantly greater reduction in C2C12 cell viability as compared to RH30). Since the MTT assay is based on the measurement of mitochondrial reductase activity to produce formazon, our results suggest that simvastatin-induced cell death may be dependent on the decrease of reductase activity in C2C12 cell lines. Of note, statin-induced myotoxicity (Graham et al., 2004) is augmented with the combination of drugs that block metabolic pathways and decrease mitochondrial reductase activity in cells, such as cytochrome P450 and UDP-

glucuronyltransferase 1A1 and 1A3 systems (Prueksaritanont et al., 2002). Consistent with previous studies, our results demonstrate that simvastatin has greater myotoxicity in C2C12 (non-cancerous muscle) cells than RH30 (skeletal muscle cancer) cells.

We also show that simvastatin induced apoptosis in a time- and dose-dependent manner in both C2C12 and RH30 cells. Interestingly, RH30 was more susceptible to apoptosis than C2C12 in 2D monolayer culture model (Figure 3). The rate of simvastatin-induced apoptosis in RH30 cells was ~2-fold greater than the C2C12 cell line. Therefore, while simvastatin caused a reduction in cell viability in C2C12 cells, these cells were also less susceptible to apoptosis than RH30 cells. This is not unexpected given that in the broader statin-cancer literature, cancer cells are predominantly more sensitive to statin-induced cell death than their normal or non-cancerous controls. These results intriguingly show that simvastatin-induced apoptosis in skeletal muscle cells does not correlate with loss of cell viability as measured by the MTT assay; this suggests an effect mediated via other mitochondrial factors. For example, in our previous investigations we showed that simvastatin-induced apoptosis is dependent on the release of Smac/Diablo and Omi/Htr2 from mitochondria in HASM cells and HAF (Ghavami et al., 2010b) and is independent of the release of cytochrome c from mitochondria.

The role of cholesterol biosynthesis in statin-induced cell death has been widely investigated and those results are consistent with ours (Graham et al., 2004; Sakamoto et al., 2007; Schirris et al., 2015b). Previous studies showed that statins reduce GGPP levels and production of ubiquinones which are used as electron carriers in the electron transport chain (Harper and Jacobson, 2007; Thompson et al., 2003). Consequently, the decrease of ubiquinone production in cells leads to dysfunction of the electron transport chain, which reduces muscle cell ATP levels, elevates free radical production, and induces apoptosis (Harper and Jacobson,

2007; Thompson et al., 2003). Further, the impaired geranylgeranylation of proteins may be a root cause in statin-associated myopathy (Cao et al., 2009; Johnson et al., 2004; Mullen et al., 2010), a concept contested by work carried out in rhabdomyosarcoma rather than normal skeletal muscle cells (Gee et al., 2015). Therefore, we decided to investigate the MA pathway in both C2C12 and RMS cells. In our study, co-treatment with MA or GGPP inhibited simvastatin-induced cell death in the C2C12 cell line while co-treatment with cholesterol and FPP did not. Takeda et al. demonstrated that the reduction of smooth muscle cell proliferation by simvastatin was inhibited by GGPP, but not by FPP (Takeda et al., 2006). Their findings are compatible with our results which show simvastatin signaling is dependent on GGPP in C2C12 cells. Our present study also shows that in RH30 cells simvastatin-induced cell death is inhibited by MA and GGPP, but not cholesterol (Fig 2). Unlike in C2C12 cells, we show that in RH30 cells simvastatin-induced cell death was inhibited by FPP (Fig 2). These findings confirm that the effect of simvastatin on cell death in both cells was mediated via inhibition of the MA pathway, in particular, GGPP. In addition, we discovered that FPP may play an important role in simvastatin-induced death mechanisms in RH30 cells.

GGPP and FPP are necessary for the prenylation of small Rho GTPase proteins including Rho, Rac, Cdc42, Rab and Rac (Alizadeh et al., 2018b; Alizadeh et al., 2017; Ghavami et al., 2010b; Ghavami et al., 2012a; Yeganeh et al., 2014). We show that simvastatin-induced cell death is dependent on GGPP in C2C12 cells. This indicates that Rho, Cdc42, and Rac GTPases may be involved in cell death induction mechanisms in C2C12 cells. Conversely, in RH30 cells both FPP and GGPP mediate simvastatin-induced cell death, suggesting that Ras GTPases may also be involved via farnesylation pathways.

438        Several recent investigations have shown that HMG-CoA reductase inhibitors such as  
439        simvastatin either induce or inhibit autophagy in different cell models (Ghavami et al., 2014;  
440        Hwang et al., 2015; Vilimanovich et al., 2015; Whitehead, 2016). There are two recent articles  
441        that showed hydrophobic statins induced autophagy in A204 RMS cells (Araki and Motojima,  
442        2008; Gee et al., 2015). But, the exact molecular mechanisms of the autophagy flux,  
443        autophagosome fusion and degradation steps of autophagy have not been investigated in RMS  
444        cells. Many studies demonstrated that the LC3-II/LC3-I ratio is often used to determine the  
445        activation of autophagy (Mizushima et al., 2010). The present results show that simvastatin  
446        increased the conversion of light chain 3 (LC3)-I to LC3-phosphatidylethanolamine conjugate  
447        (LC3-II) in both C2C12 and RH30 cells by increasing the number of LC3 puncta  
448        (immunofluorescence) and autophagosome formation (Figure 4). The protein p62 facilitates the  
449        degradation of ubiquitinated protein aggregates by autophagy (Guo et al., 2013) and is a selective  
450        substrate for autophagy and directly interacts with LC3 to mediate the degradation of  
451        ubiquitinated protein aggregates by autophagy (Pankiv et al., 2007). Our results show that  
452        simvastatin increases p62 accumulation in both RH30 and C2C12 cell lines, therefore,  
453        simvastatin inhibits autophagy flux in both cells lines. Moreover, our results showed that  
454        simvastatin induced acidification of lysosomes in RH30 cells, but in C2C12 cells simvastatin  
455        inhibited acidification of lysosomes (Fig. 4B). Taken together, our data demonstrates that  
456        simvastatin inhibits autophagy flux in a time-dependent manner in both non-cancer C2C12 and  
457        RMS RH30 cells. Therefore, we conclude that simvastatin inhibits autophagy flux in both  
458        C2C12 and RH30. In RH30 cells, autophagy inhibitory activity occurs via inhibition of  
459        lysosomal acidification, however, further investigation is required to prove this hypothesis.  
460        Further blockage of autophagy flux increases the myotoxicity of simvastatin in both C2C12 and

RH30 cells. These findings confirm the importance of autophagy flux inhibition in the myotoxicity of statins. These results are inconsistent with our findings in HAF and HASM (Ghavami et al., 2011; Ghavami et al., 2014). Also, Gu et al showed that simvastatin induces autophagy in bronchial smooth muscle cells (BSMCs) and increases autophagy-related protein Atg5, LC3B, and Beclin1 expression and autophagosome formation in lung tissue (Gu et al., 2017).

The effect of chemical compounds on cells have mostly been performed using 2D cell culture models, where cell-cell interaction, extracellular matrix, and cellular morphology significantly differ from their natural structure in tissues (Levinger et al., 2014). These differences highly influence cellular growth and their response to different chemical compounds (Levinger et al., 2014). Three-dimensional (3D) culture models have been introduced for drug assessment to improve the relation between cell cultures and cellular microenvironment (Friedrich et al., 2009). Recently, 3D culture models have been used as clinically relevant models for the study of cell death and autophagy (Gomes et al., 2015; Ma et al., 2011). We examined the effects of simvastatin in RH30 and C2C12 3D culture models (Fig. 5), which showed that simvastatin induces significantly greater cell death in RH30 cells as compared to C2C12 cells. Whereas, the cell death effects of simvastatin were greater in C2C12 cells as compared to RH30 cells in the 2D cell culture model. This shows how the cell microenvironment and 3D structure can affect fundamental cellular response(s) including to chemical compounds or drugs. We also observed that simvastatin inhibits autophagy flux in 3D culture of RH30 and C2C12 cells (absence of localization of p62 and LC3 puncta) which correlates with our 2D observations. Overall, our results indicate that 3D culture models are important tools for screening cytotoxic

effects of chemical compounds as they can account for some of the effects of cellular matrix in response to extracellular stress.

There are several limitations to this study that are important to mention. The dose of simvastatin used in our experiments (10  $\mu$ M) is significantly higher than pharmacologic concentrations found in human blood which is in the low nanogram/mL (nM) range (Ucar et al., 2000). However, we don't know if statins accumulate in human skeletal muscle, and whether they reach micromolar concentrations. Furthermore, simvastatin's half-life is approximately 2 hours in plasma, and results can vary according to which statin is selected. In addition, normal human skeletal muscle behaves differently than rhabdomyosarcoma cell line, so the effects observed could manifest differently in human normal skeletal muscle.

In conclusion, we found that simvastatin induces cell death in both RH30 and C2C12 cells in both 2D and 3D culture. Our results showed that simvastatin significantly decreases cellular viability in C2C12 cells compared to RH30 cells while it also significantly induces greater apoptosis in RH30 cells compared to C2C12 cells. In addition, simvastatin inhibits autophagy flux in both RH30 and C2C12 cells with differential effects on lysosomal acidification. We also showed that simvastatin-induced cell death is dependent on both FPP and GGPP in RH30 cells while it is only dependent on GGPP in C2C12 cells. Our current investigation provides solid evidence that both autophagy and apoptosis are involved in statin-induced myotoxicity, and further, autophagy flux inhibition varies between the non-cancerous and cancer muscle cell lines.

## **Acknowledgment**



504        Saeid Ghavami was supported by CHRIM operating grant, Research Manitoba New  
505 Investigator operating grant, CancerCare Manitoba Operating Grant and NIMAD operating  
506 grant. Shahla Shojaei was supported by HSC operating grant and Mitacs Accelerate postdoctoral  
507 award. Simone C da Silva Rosa was supported by University of Manitoba Graduate Fellowship  
508 (UMGF) PhD studentship. Joseph W Gordon was supported by NSERC Discovery grant. Ehsan  
509 Samiei was supported by a Collaborative Research and Development Grant from NSERC and  
510 BC Cancer Foundation. AZ was supported by UC Davis PI Bridge Fund.

511

## FIGURE LEGENDS:

**Figure 1: Simvastatin induces cell death in RH30 and C2C12 cells.** (A-D). RH30 cells were treated with simvastatin (0.5, 1, 2.5, 5, 10, 20  $\mu$ M) and cell viability was assessed 24, 48, 72 and 96 hrs after that by MTT assay. Control cells for each time point were treated with the solvent control (DMSO). Results are expressed as a percentage of corresponding time point control and represent the means  $\pm$  SD of 15 replicates in three independent experiments (\*,  $p<0.05$ ; \*\*\*\*,  $p<0.0001$ ). (E-H). C2C12 cells were treated with simvastatin (0.5, 1, 2.5, 5, 10, 20  $\mu$ M) and cell viability was assessed 24, 48, 72 and 96 hrs after that by MTT assay. Control cells for each time point were treated with the solvent control (DMSO). Results are expressed as a percentage of corresponding time point control and represent the means  $\pm$  SD of 15 replicates in three independent experiments (\*\*\*\*,  $p<0.0001$ ). (I&J). **Simvastatin significantly decreased cell viability in C2C12 compared to RH30 cells.** RH30 and C2C12 cells were treated with simvastatin (0.5, 1, 2.5, 5, 10, 20  $\mu$ M) and cell viability was assessed 24, 48, 72 and 96 hrs after that by MTT assay. Control cells for each time point were treated with the solvent control (DMSO). Results are expressed as a percentage of corresponding time point control and represent the means  $\pm$  SD of 15 replicates in three independent experiments (\*\*\*\*,  $p<0.0001$ ). (K&L). Phase contrast microscopy showed that simvastatin (10  $\mu$ M, 48 hrs) induces morphological changes (cellular shrinkage) and decrease in the number of cells in RH30 cells.

**Figure 2: Simvastatin induces cell death in RH30 and C2C12 cells is dependent on mevalonate cascade isoprenoid mediators.** (A-H) 5 mM MA, 30  $\mu$ M GGPP, 30  $\mu$ M FPP, or 50  $\mu$ M cholesterol, were added to the cells 4 hrs prior to treatment with simvastatin (10  $\mu$ M, 96

hrs). Cell death was measured by MTT assay in C2C12 (A-D), and RH30 cells. For each experiment control cells were treated with simvastatin solvent (DMSO) alone (control) or with both DMSO and the appropriate solvent (i.e. ethanol for “mevalonate control). Mevalonate (A, E) and GGPP (B, F) significantly inhibited simvastatin induced cell death in both C2C12 and RH30 cells while FPP (C, G) only inhibited simvastatin-induced cell death in RH30 cells. Our results also showed that cholesterol (D, H) is not involved in simvastatin induced cell death in C2C12 and RH30 cells. Results are expressed as mean  $\pm$  SD of 15 replicate in 3 independent experiments (\*  $p < 0.05$ , \*\*\*  $p < 0.001$ , and \*\*\*\*  $p < 0.0001$ ). (I&J) Our results also showed that FPP (I) and GGPP (J) significantly rescues simvastatin induced cell death in RH30 cells compared to C2C12 cells.

**Figure 3: Simvastatin induces dose and time depended apoptosis cell death in C2C12 and RH30 cells.** Percent sub-G1 (A-C) C2C12, (D-F) RH30, abundance induced by simvastatin (5, and 10  $\mu$ M) or DMSO solvent control after 48 and 72 hrs. Results represent the means  $\pm$  SD of 9 replicates in three independent experiments. \*\*\*\*  $p < 0.0001$ ; and \*\*\*  $p < 0.001$  compared to time-matched control. Representative figures of the flow cytometry histogram for C2C12 and RH30 are shown (A and D). Our results showed that simvastatin (10  $\mu$ M) induced significant more apoptosis in RH30 compared to C2C12 cells in 48 (G) and 72 (H) hours (\*\*  $p < 0.01$ , and \*\*\*\*  $p < 0.0001$ ).

**Figure 4: Simvastatin inhibits autophagy flux inhibition in C2C12 and RH30 cells.** (A) C2C12 and RH30 cells were treated with simvastatin (10  $\mu$ M, 0-72 hours) and cell lysates were

collected. Immunoblotting for LC3 $\beta$  and p62 were performed. The results showed that simvastatin induced accumulation of LC3 $\beta$  II and inhibits p62 degradation in both C2C12 and RH30 cells. C2C12 and C2C12 cells were treated with simvastatin (10  $\mu$ M, 24 h). (B-D) using immunocytochemistry LC3 puncta and changes in lysosomal activity (LysoTracker red staining) has been investigated. The results showed that simvastatin increased LC3 puncta in both cell lines. Our results also showed that simvastatin (10  $\mu$ M, 24 hours) increase lysosomal acidity in RH30 while inhibits lysosomal acidification in C2C12 cells (B). C2C12 (E) and RH30 (F) cells were treated with simvastatin (10  $\mu$ M, 24h) and Baf-A1 (100 nM, +3 hours) followed by immunocytochemistry to evaluate LC3 puncta and changes in lysosomal activity (LysoTracker red staining). The results showed that simvastatin increased LC3 puncta and decreased LysoTracker red fluorescence intensity in C2C12 cells while increased LC3 puncta and increased LysoTracker red fluorescence intensity in RH30 cells. On the other hand, Baf-A1 and simvastatin + Baf-A1 did not significantly change LC3 puncta in both C2C12 and RH30 cells (G, H) showing that simvastatin inhibited autophagy flux like Baf-A1. Transmission electron microscopy showed that in treated C2C12 (I) and RH30 (J) cells there are accumulated autophagosome-like structures compared to control and normal cells after 72 hours treatment. Arrows show the autophagolysosomes containing the cargo (magnification  $\times$ 11,600). Autophagy inhibition (Baf-A1, 4 nM, 24 hours) significantly increased simvastatin-induced cell death (10  $\mu$ M, 24 hours) in RH30 (L) and C2C12 (M) cell lines (\*\*  $p < 0.01$ , Results represent the means  $\pm$  SD of 15 replicates in three independent experiments). Baf-A1 (4 nM) and simvastatin (10  $\mu$ M) combination did not increase accumulation of LC3 $\beta$ -II and p62 in both RH30 and C2C12 cells (K).

**Figure 5: Simvastatin induces apoptosis and autophagy in C2C12 and RH30 3D culture.**

(A&B). Bright field image of C2C12 (A) and RH30 (B) 3D culture which shows the morphology of untreated and simvastatin treated cells (5, 10  $\mu$ M, 96 hours) in 3D culture. (C-H). Viability assay was done by adding the live/dead solution to cells 48 and 96 hours after treatment with simvastatin (0–20  $\mu$ M). Cells were incubated for 2 hours in the dark at room temperature, rinsed three times with DPBS, and confocal microscopy was used to capture live/dead cell images in C2C12 (C) and RH30 (D) cells. Quantification of live/dead assay was measured by calculating the ratio of live: total cells which showed a significant decrease in viability of C2C12 (E&F) and RH30 (G&H) cells treated with different concentrations of simvastatin. The data showed simvastatin significantly induces cell death in both C2C12 and RH30 cells ( $P < 0.0001$ ) while simvastatin induces more cell death in RH30 compared to C2C12 cells. (I&J) IF labeling of C2C12 cells (I) and RH30 cells (J) by cleaved PARP following treatment with simvastatin (10  $\mu$ M, 48 hours) increased number of cells with cleaved PARP in simvastatin treated cells in comparison to control cells which is the hallmark of increase of apoptosis in these cells. (K&L) After treatment of C2C12 (K) and RH30 (L) cells with simvastatin (10  $\mu$ M, 48 h), cells were IF labeled with autophagosome markers, LC3 and P62. Data showed that simvastatin increases LC3 puncta (green) which is not localized with p62 compared to corresponding time-matched control, a hallmark of autophagy flux inhibition in C2C12 and RH30 3D culture

601

602 **REFERENCES:**

603 Alizadeh, J., Glogowska, A., Thliveris, J., Kalantari, F., Shojaei, S., Hombach-Klonisch, S.,  
604 Klonisch, T., Ghavami, S., 2018a. Autophagy modulates transforming growth factor beta 1  
605 induced epithelial to mesenchymal transition in non-small cell lung cancer cells. *Biochim*  
606 *Biophys Acta Mol Cell Res* 1865, 749-768.

607 Alizadeh, J., Shojaei, S., da Silva Rosa, S., Rezaei Moghadam, A., Zeki, A.A., Hashemi, M.,  
608 Los, M.J., Gordon, J.W., Ghavami, S., 2018b. Detection of Small GTPase Prenylation and GTP  
609 Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay. *Journal of*  
610 *visualized experiments : JoVE*.

611 Alizadeh, J., Zeki, A.A., Mirzaei, N., Tewary, S., Rezaei Moghadam, A., Glogowska, A.,  
612 Nagakannan, P., Eftekharpour, E., Wiechec, E., Gordon, J.W., Xu, F.Y., Field, J.T., Yoneda,  
613 K.Y., Kenyon, N.J., Hashemi, M., Hatch, G.M., Hombach-Klonisch, S., Klonisch, T., Ghavami,  
614 S., 2017. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway  
615 via Depletion of Isoprenoids in Tumor Cells. *Scientific reports* 7, 44841.

616 Amiri, S., Dastghaib, S., Ahmadi, M., Mehrbod, P., Khadem, F., Behrooj, H., Aghanoori, M.R.,  
617 Machaj, F., Ghamsari, M., Rosik, J., Hudecki, A., Afkhami, A., Hashemi, M., Los, M.J.,  
618 Mokarram, P., Madrakian, T., Ghavami, S., 2019. Betulin and its derivatives as novel  
619 compounds with different pharmacological effects. *Biotechnol Adv*.

620 Araki, M., Motojima, K., 2008. Hydrophobic statins induce autophagy in cultured human  
621 rhabdomyosarcoma cells. *Biochem Biophys Res Commun* 367, 462-467.

622 Baba, T.T., Nemoto, T.K., Miyazaki, T., Oida, S., 2008. Simvastatin suppresses the  
623 differentiation of C2C12 myoblast cells via a Rac pathway. *J Muscle Res Cell Motil* 29, 127-  
624 134.

625 Ballantyne, C.M., Corsini, A., Davidson, M.H., Holdaas, H., Jacobson, T.A., Leitersdorf, E.,  
626 Marz, W., Reckless, J.P., Stein, E.A., 2003. Risk for myopathy with statin therapy in high-risk  
627 patients. *Arch Intern Med* 163, 553-564.

628 Bhardwaj, S., Selvarajah, S., Schneider, E.B., 2013. Muscular effects of statins in the elderly  
629 female: a review. *Clin Interv Aging* 8, 47-59.

630 Bouitbir, J., Charles, A.L., Echaniz-Laguna, A., Kindo, M., Daussin, F., Auwerx, J., Piquard, F.,  
631 Geny, B., Zoll, J., 2012. Opposite effects of statins on mitochondria of cardiac and skeletal  
632 muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. *European*  
633 *heart journal* 33, 1397-1407.

634 Cao, P., Hanai, J., Tanksale, P., Imamura, S., Sukhatme, V.P., Lecker, S.H., 2009. Statin-induced  
635 muscle damage and atrogen-1 induction is the result of a geranylgeranylation defect. *FASEB*  
636 *journal : official publication of the Federation of American Societies for Experimental Biology*  
637 23, 2844-2854.

638 Cartocci, V., Servadio, M., Trezza, V., Pallottini, V., 2017. Can Cholesterol Metabolism  
639 Modulation Affect Brain Function and Behavior? *J Cell Physiol* 232, 281-286.

640 Crick, D.C., Andres, D.A., Waechter, C.J., 1997. Novel salvage pathway utilizing farnesol and  
641 geranylgeraniol for protein isoprenylation. *Biochem Biophys Res Commun* 237, 483-487.

642 Dricu, A., Wang, M., Hjertman, M., Malec, M., Blegen, H., Wejde, J., Carlberg, M., Larsson, O.,  
643 1997. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in

644 expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras  
645 prenylation and expression of c-myc. *Glycobiology* 7, 625-633.

646 Endo, A., Tsujita, Y., Kuroda, M., Tanzawa, K., 1977. Inhibition of cholesterol synthesis in vitro  
647 and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-  
648 coenzyme A reductase. *Eur J Biochem* 77, 31-36.

649 Field, J.T., Martens, M.D., Mughal, W., Hai, Y., Chapman, D., Hatch, G.M., Ivanco, T.L., Diehl-  
650 Jones, W., Gordon, J.W., 2018. Misoprostol regulates Bnip3 repression and alternative splicing  
651 to control cellular calcium homeostasis during hypoxic stress. *Cell Death Discov* 4, 37.

652 Friedrich, J., Seidel, C., Ebner, R., Kunz-Schughart, L.A., 2009. Spheroid-based drug screen:  
653 considerations and practical approach. *Nature protocols* 4, 309-324.

654 Gee, R.H., Spinks, J.N., Malia, J.M., Johnston, J.D., Plant, N.J., Plant, K.E., 2015. Inhibition of  
655 prenyltransferase activity by statins in both liver and muscle cell lines is not causative of  
656 cytotoxicity. *Toxicology* 329, 40-48.

657 Ghavami, S., Eshragi, M., Ande, S.R., Chazin, W.J., Klonisch, T., Halayko, A.J., McNeill, K.D.,  
658 Hashemi, M., Kerkhoff, C., Los, M., 2010a. S100A8/A9 induces autophagy and apoptosis via  
659 ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. *Cell Res*  
660 20, 314-331.

661 Ghavami, S., Kerkhoff, C., Los, M., Hashemi, M., Sorg, C., Karami-Tehrani, F., 2004.  
662 Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and  
663 the effect of metal ions. *J Leukoc Biol* 76, 169-175.

664 Ghavami, S., Mutawe, M.M., Hauff, K., Stelmack, G.L., Schaafsma, D., Sharma, P., McNeill,  
665 K.D., Hynes, T.S., Kung, S.K., Unruh, H., Klonisch, T., Hatch, G.M., Los, M., Halayko, A.J.,  
666 2010b. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-



667 PUMA and release of Smac and Omi but not cytochrome c. *Biochimica et biophysica acta* 1803,  
668 452-467.

669 Ghavami, S., Mutawe, M.M., Schaafsma, D., Yeganeh, B., Unruh, H., Klonisch, T., Halayko,  
670 A.J., 2012a. Geranylgeranyl transferase 1 modulates autophagy and apoptosis in human airway  
671 smooth muscle. *American journal of physiology. Lung cellular and molecular physiology* 302,  
672 L420-428.

673 Ghavami, S., Mutawe, M.M., Sharma, P., Yeganeh, B., McNeill, K.D., Klonisch, T., Unruh, H.,  
674 Kashani, H.H., Schaafsma, D., Los, M., Halayko, A.J., 2011. Mevalonate cascade regulation of  
675 airway mesenchymal cell autophagy and apoptosis: a dual role for p53. *PloS one* 6, e16523.

676 Ghavami, S., Sharma, P., Yeganeh, B., Ojo, O.O., Jha, A., Mutawe, M.M., Kashani, H.H., Los,  
677 M.J., Klonisch, T., Unruh, H., Halayko, A.J., 2014. Airway mesenchymal cell death by  
678 mevalonate cascade inhibition: integration of autophagy, unfolded protein response and  
679 apoptosis focusing on Bcl2 family proteins. *Biochimica et biophysica acta* 1843, 1259-1271.

680 Ghavami, S., Yeganeh, B., Stelmack, G.L., Kashani, H.H., Sharma, P., Cunningham, R., Rattan,  
681 S., Bathe, K., Klonisch, T., Dixon, I.M., Freed, D.H., Halayko, A.J., 2012b. Apoptosis,  
682 autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial  
683 fibroblasts. *Cell Death Dis* 3, e330.

684 Gomes, L.R., Vessoni, A.T., Menck, C.F., 2015. Three-dimensional microenvironment confers  
685 enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy.  
686 *Oncogene* 34, 5329-5340.

687 Graham, D.J., Staffa, J.A., Shatin, D., Andrade, S.E., Schech, S.D., La Grenade, L., Gurwitz,  
688 J.H., Chan, K.A., Goodman, M.J., Platt, R., 2004. Incidence of hospitalized rhabdomyolysis in  
689 patients treated with lipid-lowering drugs. *Jama* 292, 2585-2590.

690 Grundy, S.M., Vega, G.L., 1985. Influence of mevinolin on metabolism of low density  
691 lipoproteins in primary moderate hypercholesterolemia. *J Lipid Res* 26, 1464-1475.

692 Gu, W., Cui, R., Ding, T., Li, X., Peng, J., Xu, W., Han, F., Guo, X., 2017. Simvastatin alleviates  
693 airway inflammation and remodelling through up-regulation of autophagy in mouse models of  
694 asthma. *Respirology (Carlton, Vic.)* 22, 533-541.

695 Guo, X., Dong, Y., Yin, S., Zhao, C., Huo, Y., Fan, L., Hu, H., 2013. Patulin induces pro-  
696 survival functions via autophagy inhibition and p62 accumulation. *Cell Death Dis* 4, e822.

697 Harper, C.R., Jacobson, T.A., 2007. The broad spectrum of statin myopathy: from myalgia to  
698 rhabdomyolysis. *Current opinion in lipidology* 18, 401-408.

699 Hashemi, M., Ghavami, S., Eshraghi, M., Booy, E.P., Los, M., 2007. Cytotoxic effects of intra-  
700 and extracellular zinc chelation on human breast cancer cells. *Eur J Pharmacol* 557, 9-19.

701 Hashemi, M., Hoshyar, R., Ande, S.R., Chen, Q.M., Solomon, C., Zuse, A., Naderi, M., 2017.  
702 Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health  
703 and Disease. *Curr Mol Pharmacol* 10, 13-26.

704 Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A.,  
705 Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B.D., Hoshyar, R., Seyfoori, A., Sepehri, Z.,  
706 Ande, S.R., Khadem, F., Akbari, M., Gorman, A.M., Samali, A., Klonisch, T., Ghavami, S.,  
707 2018. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis,  
708 autophagy, and unfolded protein response. *Pharmacol Ther* 184, 13-41.

709 Hwang, K.E., Kim, Y.S., Jung, J.W., Kwon, S.J., Park, D.S., Cha, B.K., Oh, S.H., Yoon, K.H.,  
710 Jeong, E.T., Kim, H.R., 2015. Inhibition of autophagy potentiates pemetrexed and simvastatin-  
711 induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.  
712 *Oncotarget* 6, 29482-29496.

713 Illingworth, D.R., Sexton, G.J., 1984. Hypocholesterolemic effects of mevinolin in patients with  
714 heterozygous familial hypercholesterolemia. *J Clin Invest* 74, 1972-1978.

715 Jaskiewicz, A., Pajak, B., Labieniec-Watala, M., Palma, C., Orzechowski, A., 2019. Diverse  
716 Action of Selected Statins on Skeletal Muscle Cells-An Attempt to Explain the Protective Effect  
717 of Geranylgeraniol (GGOH) in Statin-Associated Myopathy (SAM). *J Clin Med* 8.

718 Jiao, X., Ashtari, N., Rahimi-Balaei, M., Chen, Q.M., Badbezanchi, I., Shojaei, S., Marzban, A.,  
719 Mirzaei, N., Chung, S., Guan, T., Li, J., Vriend, J., Mehr, S.E., Kong, J., Marzban, H., 2017.  
720 Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets  
721 for Therapeutic Application. *Curr Mol Pharmacol* 10, 115-140.

722 Johnson, T.E., Zhang, X., Bleicher, K.B., Dysart, G., Loughlin, A.F., Schaefer, W.H.,  
723 Umbenhauer, D.R., 2004. Statins induce apoptosis in rat and human myotube cultures by  
724 inhibiting protein geranylgeranylation but not ubiquinone. *Toxicology and applied pharmacology*  
725 200, 237-250.

726 Klionsky, D.J., Abdelmohsen, K., Abe, A., Abedin, M.J., Abeliovich, H., Acevedo Arozena, A.,  
727 Adachi, H., Adams, C.M., Adams, P.D., Adeli, K., Adhihetty, P.J., Adler, S.G., Agam, G.,  
728 Agarwal, R., Aghi, M.K., Agnello, M., Agostinis, P., Aguilar, P.V., Aguirre-Ghiso, J., Airoidi,  
729 E.M., Ait-Si-Ali, S., Akematsu, T., Akporiaye, E.T., Al-Rubeai, M., Albaiceta, G.M., Albanese,  
730 C., Albani, D., Albert, M.L., Aldudo, J., Algul, H., Alirezai, M., Alloza, I., Almasan, A.,  
731 Almonte-Beceril, M., Alnemri, E.S., Alonso, C., Altan-Bonnet, N., Altieri, D.C., Alvarez, S.,  
732 Alvarez-Erviti, L., Alves, S., Amadoro, G., Amano, A., Amantini, C., Ambrosio, S., Amelio, I.,  
733 Amer, A.O., Amessou, M., Amon, A., An, Z., Anania, F.A., Andersen, S.U., Andley, U.P.,  
734 Andreadi, C.K., Andrieu-Abadie, N., Anel, A., Ann, D.K., Anoopkumar-Dukie, S., Antonioli,  
735 M., Aoki, H., Apostolova, N., Aquila, S., Aquilano, K., Araki, K., Arama, E., Aranda, A., Araya,

736 J., Arcaro, A., Arias, E., Arimoto, H., Ariosa, A.R., Armstrong, J.L., Arnould, T., Arsov, I.,  
 737 Asanuma, K., Askanas, V., Asselin, E., Atarashi, R., Atherton, S.S., Atkin, J.D., Attardi, L.D.,  
 738 Auburger, P., Auburger, G., Aurelian, L., Autelli, R., Avagliano, L., Avantaggiati, M.L.,  
 739 Avrahami, L., Awale, S., Azad, N., Bachetti, T., Backer, J.M., Bae, D.H., Bae, J.S., Bae, O.N.,  
 740 Bae, S.H., Baehrecke, E.H., Baek, S.H., Baghdiguian, S., Bagniewska-Zadworna, A., Bai, H.,  
 741 Bai, J., Bai, X.Y., Bailly, Y., Balaji, K.N., Balduini, W., Ballabio, A., Balzan, R., Banerjee, R.,  
 742 Banhegyi, G., Bao, H., Barbeau, B., Barrachina, M.D., Barreiro, E., Bartel, B., Bartolome, A.,  
 743 Bassham, D.C., Bassi, M.T., Bast, R.C., Jr., Basu, A., Batista, M.T., Batoko, H., Battino, M.,  
 744 Bauckman, K., Baumgarner, B.L., Bayer, K.U., Beale, R., Beaulieu, J.F., Beck, G.R., Jr., Becker,  
 745 C., Beckham, J.D., Bedard, P.A., Bednarski, P.J., Begley, T.J., Behl, C., Behrends, C., Behrens,  
 746 G.M., Behrns, K.E., Bejarano, E., Belaid, A., Belleudi, F., Benard, G., Berchem, G.,  
 747 Bergamaschi, D., Bergami, M., Berkhout, B., Berliocchi, L., Bernard, A., Bernard, M.,  
 748 Bernassola, F., Bertolotti, A., Bess, A.S., Besteiro, S., Bettuzzi, S., Bhalla, S., Bhattacharyya, S.,  
 749 Bhutia, S.K., Biagosch, C., Bianchi, M.W., Biard-Piechaczyk, M., Billes, V., Bincoletto, C.,  
 750 Bingol, B., Bird, S.W., Bitoun, M., Bjedov, I., Blackstone, C., Blanc, L., Blanco, G.A.,  
 751 Blomhoff, H.K., Boada-Romero, E., Bockler, S., Boes, M., Boesze-Battaglia, K., Boise, L.H.,  
 752 Bolino, A., Boman, A., Bonaldo, P., Bordi, M., Bosch, J., Botana, L.M., Botti, J., Bou, G.,  
 753 Bouche, M., Bouchecareilh, M., Boucher, M.J., Boulton, M.E., Bouret, S.G., Boya, P., Boyer-  
 754 Guittaut, M., Bozhkov, P.V., Brady, N., Braga, V.M., Brancolini, C., Braus, G.H., Bravo-San  
 755 Pedro, J.M., Brennan, L.A., Bresnick, E.H., Brest, P., Bridges, D., Bringer, M.A., Brini, M.,  
 756 Brito, G.C., Brodin, B., Brookes, P.S., Brown, E.J., Brown, K., Broxmeyer, H.E., Bruhat, A.,  
 757 Brum, P.C., Brumell, J.H., Brunetti-Pierri, N., Bryson-Richardson, R.J., Buch, S., Buchan, A.M.,  
 758 Budak, H., Bulavin, D.V., Bultman, S.J., Bultynck, G., Bumbasirevic, V., Burelle, Y., Burke,

759 R.E., Burmeister, M., Butikofer, P., Caberlotto, L., Cadwell, K., Cahova, M., Cai, D., Cai, J.,  
 760 Cai, Q., Calatayud, S., Camougrand, N., Campanella, M., Campbell, G.R., Campbell, M.,  
 761 Campello, S., Candau, R., Caniggia, I., Cantoni, L., Cao, L., Caplan, A.B., Caraglia, M.,  
 762 Cardinali, C., Cardoso, S.M., Carew, J.S., Carleton, L.A., Carlin, C.R., Carloni, S., Carlsson,  
 763 S.R., Carmona-Gutierrez, D., Carneiro, L.A., Carnevali, O., Carra, S., Carrier, A., Carroll, B.,  
 764 Casas, C., Casas, J., Cassinelli, G., Castets, P., Castro-Obregon, S., Cavallini, G., Ceccherini, I.,  
 765 Cecconi, F., Cederbaum, A.I., Cena, V., Cenci, S., Cerella, C., Cervia, D., Cetrullo, S.,  
 766 Chaachouay, H., Chae, H.J., Chagin, A.S., Chai, C.Y., Chakrabarti, G., Chamilos, G., Chan,  
 767 E.Y., Chan, M.T., Chandra, D., Chandra, P., Chang, C.P., Chang, R.C., Chang, T.Y., Chatham,  
 768 J.C., Chatterjee, S., Chauhan, S., Che, Y., Cheetham, M.E., Cheluvappa, R., Chen, C.J., Chen,  
 769 G., Chen, G.C., Chen, G., Chen, H., Chen, J.W., Chen, J.K., Chen, M., Chen, M., Chen, P.,  
 770 Chen, Q., Chen, Q., Chen, S.D., Chen, S., Chen, S.S., Chen, W., Chen, W.J., Chen, W.Q., Chen,  
 771 W., Chen, X., Chen, Y.H., Chen, Y.G., Chen, Y., Chen, Y., Chen, Y., Chen, Y.J., Chen, Y.Q.,  
 772 Chen, Y., Chen, Z., Chen, Z., Cheng, A., Cheng, C.H., Cheng, H., Cheong, H., Cherry, S.,  
 773 Chesney, J., Cheung, C.H., Chevet, E., Chi, H.C., Chi, S.G., Chiacchiera, F., Chiang, H.L.,  
 774 Chiarelli, R., Chiariello, M., Chieppa, M., Chin, L.S., Chiong, M., Chiu, G.N., Cho, D.H., Cho,  
 775 S.G., Cho, W.C., Cho, Y.Y., Cho, Y.S., Choi, A.M., Choi, E.J., Choi, E.K., Choi, J., Choi, M.E.,  
 776 Choi, S.I., Chou, T.F., Chouaib, S., Choubey, D., Choubey, V., Chow, K.C., Chowdhury, K.,  
 777 Chu, C.T., Chuang, T.H., Chun, T., Chung, H., Chung, T., Chung, Y.L., Chwae, Y.J.,  
 778 Cianfanelli, V., Ciarcia, R., Ciechomska, I.A., Ciriolo, M.R., Cirone, M., Claerhout, S., Clague,  
 779 M.J., Claria, J., Clarke, P.G., Clarke, R., Clementi, E., Cleyrat, C., Cnop, M., Coccia, E.M.,  
 780 Cocco, T., Codogno, P., Coers, J., Cohen, E.E., Colecchia, D., Coletto, L., Coll, N.S., Colucci-  
 781 Guyon, E., Comincini, S., Condello, M., Cook, K.L., Coombs, G.H., Cooper, C.D., Cooper,

782 J.M., Coppens, I., Corasaniti, M.T., Corazzari, M., Corbalan, R., Corcelle-Termeau, E., Cordero,  
 783 M.D., Corral-Ramos, C., Corti, O., Cossarizza, A., Costelli, P., Costes, S., Cotman, S.L., Coto-  
 784 Montes, A., Cottet, S., Couve, E., Covey, L.R., Cowart, L.A., Cox, J.S., Coxon, F.P., Coyne,  
 785 C.B., Cragg, M.S., Craven, R.J., Crepaldi, T., Crespo, J.L., Criollo, A., Crippa, V., Cruz, M.T.,  
 786 Cuervo, A.M., Cuezva, J.M., Cui, T., Cutillas, P.R., Czaja, M.J., Czyzyk-Krzeska, M.F., Dagda,  
 787 R.K., Dahmen, U., Dai, C., Dai, W., Dai, Y., Dalby, K.N., Dalla Valle, L., Dalmaso, G.,  
 788 D'Amelio, M., Damme, M., Darfeuille-Michaud, A., Dargemont, C., Darley-Usmar, V.M.,  
 789 Dasarathy, S., Dasgupta, B., Dash, S., Dass, C.R., Davey, H.M., Davids, L.M., Davila, D., Davis,  
 790 R.J., Dawson, T.M., Dawson, V.L., Daza, P., de Belleruche, J., de Figueiredo, P., de Figueiredo,  
 791 R.C., de la Fuente, J., De Martino, L., De Matteis, A., De Meyer, G.R., De Milito, A., De Santi,  
 792 M., de Souza, W., De Tata, V., De Zio, D., Debnath, J., Dechant, R., Decuypere, J.P., Deegan,  
 793 S., Dehay, B., Del Bello, B., Del Re, D.P., Delage-Mourroux, R., Delbridge, L.M., Deldicque,  
 794 L., Delorme-Axford, E., Deng, Y., Dengjel, J., Denizot, M., Dent, P., Der, C.J., Deretic, V.,  
 795 Derrien, B., Deutsch, E., Devarenne, T.P., Devenish, R.J., Di Bartolomeo, S., Di Daniele, N., Di  
 796 Domenico, F., Di Nardo, A., Di Paola, S., Di Pietro, A., Di Renzo, L., DiAntonio, A., Diaz-  
 797 Araya, G., Diaz-Laviada, I., Diaz-Meco, M.T., Diaz-Nido, J., Dickey, C.A., Dickson, R.C.,  
 798 Diederich, M., Digard, P., Dikic, I., Dinesh-Kumar, S.P., Ding, C., Ding, W.X., Ding, Z., Dini,  
 799 L., Distler, J.H., Diwan, A., Djavaheri-Mergny, M., Dmytruk, K., Dobson, R.C., Doetsch, V.,  
 800 Dokladny, K., Dokudovskaya, S., Donadelli, M., Dong, X.C., Dong, X., Dong, Z., Donohue,  
 801 T.M., Jr., Doran, K.S., D'Orazi, G., Dorn, G.W., 2nd, Dosenko, V., Dridi, S., Drucker, L., Du, J.,  
 802 Du, L.L., Du, L., du Toit, A., Dua, P., Duan, L., Duann, P., Dubey, V.K., Duchen, M.R.,  
 803 Duchosal, M.A., Duez, H., Dugail, I., Dumit, V.I., Duncan, M.C., Dunlop, E.A., Dunn, W.A., Jr.,  
 804 Dupont, N., Dupuis, L., Duran, R.V., Durcan, T.M., Duvezin-Caubet, S., Duvvuri, U., Eapen, V.,

805 Ebrahimi-Fakhari, D., Echard, A., Eckhart, L., Edelstein, C.L., Edinger, A.L., Eichinger, L.,  
 806 Eisenberg, T., Eisenberg-Lerner, A., Eissa, N.T., El-Deiry, W.S., El-Khoury, V., Elazar, Z.,  
 807 Eldar-Finkelman, H., Elliott, C.J., Emanuele, E., Emmenegger, U., Engedal, N., Engelbrecht,  
 808 A.M., Engelender, S., Enserink, J.M., Erdmann, R., Erenpreisa, J., Eri, R., Eriksen, J.L., Erman,  
 809 A., Escalante, R., Eskelinen, E.L., Espert, L., Esteban-Martinez, L., Evans, T.J., Fabri, M.,  
 810 Fabrias, G., Fabrizi, C., Facchiano, A., Faergeman, N.J., Faggioni, A., Fairlie, W.D., Fan, C.,  
 811 Fan, D., Fan, J., Fang, S., Fanto, M., Fanzani, A., Farkas, T., Faure, M., Favier, F.B., Fearnhead,  
 812 H., Federici, M., Fei, E., Felizardo, T.C., Feng, H., Feng, Y., Feng, Y., Ferguson, T.A.,  
 813 Fernandez, A.F., Fernandez-Barrena, M.G., Fernandez-Checa, J.C., Fernandez-Lopez, A.,  
 814 Fernandez-Zapico, M.E., Feron, O., Ferraro, E., Ferreira-Halder, C.V., Fesus, L., Feuer, R.,  
 815 Fiesel, F.C., Filippi-Chiela, E.C., Filomeni, G., Fimia, G.M., Fingert, J.H., Finkbeiner, S., Finkel,  
 816 T., Fiorito, F., Fisher, P.B., Flajolet, M., Flamigni, F., Florey, O., Florio, S., Floto, R.A., Folini,  
 817 M., Follo, C., Fon, E.A., Fornai, F., Fortunato, F., Fraldi, A., Franco, R., Francois, A., Francois,  
 818 A., Frankel, L.B., Fraser, I.D., Frey, N., Freyssenet, D.G., Frezza, C., Friedman, S.L., Frigo,  
 819 D.E., Fu, D., Fuentes, J.M., Fueyo, J., Fujitani, Y., Fujiwara, Y., Fujiya, M., Fukuda, M., Fulda,  
 820 S., Fusco, C., Gabryel, B., Gaestel, M., Gailly, P., Gajewska, M., Galadari, S., Galili, G.,  
 821 Galindo, I., Galindo, M.F., Galliciotti, G., Galluzzi, L., Galluzzi, L., Galy, V., Gammoh, N.,  
 822 Gandy, S., Ganesan, A.K., Ganesan, S., Ganley, I.G., Gannage, M., Gao, F.B., Gao, F., Gao,  
 823 J.X., Garcia Nannig, L., Garcia Vescovi, E., Garcia-Macia, M., Garcia-Ruiz, C., Garg, A.D.,  
 824 Garg, P.K., Gargini, R., Gassen, N.C., Gatica, D., Gatti, E., Gavard, J., Gavathiotis, E., Ge, L.,  
 825 Ge, P., Ge, S., Gean, P.W., Gelmetti, V., Genazzani, A.A., Geng, J., Genschik, P., Gerner, L.,  
 826 Gestwicki, J.E., Gewirtz, D.A., Ghavami, S., Ghigo, E., Ghosh, D., Giammarioli, A.M.,  
 827 Giampieri, F., Giampietri, C., Giatromanolaki, A., Gibbings, D.J., Gibellini, L., Gibson, S.B.,

828 Ginet, V., Giordano, A., Giorgini, F., Giovannetti, E., Girardin, S.E., Gispert, S., Giuliano, S.,  
 829 Gladson, C.L., Glavic, A., Gleave, M., Godefroy, N., Gogal, R.M., Jr., Gokulan, K., Goldman,  
 830 G.H., Goletti, D., Goligorsky, M.S., Gomes, A.V., Gomes, L.C., Gomez, H., Gomez-Manzano,  
 831 C., Gomez-Sanchez, R., Goncalves, D.A., Goncu, E., Gong, Q., Gongora, C., Gonzalez, C.B.,  
 832 Gonzalez-Alegre, P., Gonzalez-Cabo, P., Gonzalez-Polo, R.A., Goping, I.S., Gorbea, C.,  
 833 Gorbunov, N.V., Goring, D.R., Gorman, A.M., Gorski, S.M., Goruppi, S., Goto-Yamada, S.,  
 834 Gotor, C., Gottlieb, R.A., Gozes, I., Gozuacik, D., Graba, Y., Graef, M., Granato, G.E., Grant,  
 835 G.D., Grant, S., Gravina, G.L., Green, D.R., Greenhough, A., Greenwood, M.T., Grimaldi, B.,  
 836 Gros, F., Grose, C., Groulx, J.F., Gruber, F., Grumati, P., Grune, T., Guan, J.L., Guan, K.L.,  
 837 Guerra, B., Guillen, C., Gulshan, K., Gunst, J., Guo, C., Guo, L., Guo, M., Guo, W., Guo, X.G.,  
 838 Gust, A.A., Gustafsson, A.B., Gutierrez, E., Gutierrez, M.G., Gwak, H.S., Haas, A., Haber, J.E.,  
 839 Hadano, S., Hagedorn, M., Hahn, D.R., Halayko, A.J., Hamacher-Brady, A., Hamada, K.,  
 840 Hamai, A., Hamann, A., Hamasaki, M., Hamer, I., Hamid, Q., Hammond, E.M., Han, F., Han,  
 841 W., Handa, J.T., Hanover, J.A., Hansen, M., Harada, M., Harhaji-Trajkovic, L., Harper, J.W.,  
 842 Harrath, A.H., Harris, A.L., Harris, J., Hasler, U., Hasselblatt, P., Hasui, K., Hawley, R.G.,  
 843 Hawley, T.S., He, C., He, C.Y., He, F., He, G., He, R.R., He, X.H., He, Y.W., He, Y.Y., Heath,  
 844 J.K., Hebert, M.J., Heinzen, R.A., Helgason, G.V., Hensel, M., Henske, E.P., Her, C., Herman,  
 845 P.K., Hernandez, A., Hernandez, C., Hernandez-Tiedra, S., Hetz, C., Hiesinger, P.R., Higaki, K.,  
 846 Hilfiker, S., Hill, B.G., Hill, J.A., Hill, W.D., Hino, K., Hofius, D., Hofman, P., Hoglinger, G.U.,  
 847 Hohfeld, J., Holz, M.K., Hong, Y., Hood, D.A., Hoozemans, J.J., Hoppe, T., Hsu, C., Hsu, C.Y.,  
 848 Hsu, L.C., Hu, D., Hu, G., Hu, H.M., Hu, H., Hu, M.C., Hu, Y.C., Hu, Z.W., Hua, F., Hua, Y.,  
 849 Huang, C., Huang, H.L., Huang, K.H., Huang, K.Y., Huang, S., Huang, S., Huang, W.P., Huang,  
 850 Y.R., Huang, Y., Huang, Y., Huber, T.B., Huebbe, P., Huh, W.K., Hulmi, J.J., Hur, G.M.,



851 Hurley, J.H., Husak, Z., Hussain, S.N., Hussain, S., Hwang, J.J., Hwang, S., Hwang, T.I.,  
 852 Ichihara, A., Imai, Y., Imbriano, C., Inomata, M., Into, T., Iovane, V., Iovanna, J.L., Iozzo, R.V.,  
 853 Ip, N.Y., Irazoqui, J.E., Iribarren, P., Isaka, Y., Isakovic, A.J., Ischiropoulos, H., Isenberg, J.S.,  
 854 Ishaq, M., Ishida, H., Ishii, I., Ishmael, J.E., Isidoro, C., Isobe, K., Isono, E., Issazadeh-Navikas,  
 855 S., Itahana, K., Itakura, E., Ivanov, A.I., Iyer, A.K., Izquierdo, J.M., Izumi, Y., Izzo, V., Jaattela,  
 856 M., Jaber, N., Jackson, D.J., Jackson, W.T., Jacob, T.G., Jacques, T.S., Jagannath, C., Jain, A.,  
 857 Jana, N.R., Jang, B.K., Jani, A., Janji, B., Jannig, P.R., Jansson, P.J., Jean, S., Jendrach, M.,  
 858 Jeon, J.H., Jessen, N., Jeung, E.B., Jia, K., Jia, L., Jiang, H., Jiang, H., Jiang, L., Jiang, T., Jiang,  
 859 X., Jiang, X., Jiang, X., Jiang, Y., Jiang, Y., Jimenez, A., Jin, C., Jin, H., Jin, L., Jin, M., Jin, S.,  
 860 Jinwal, U.K., Jo, E.K., Johansen, T., Johnson, D.E., Johnson, G.V., Johnson, J.D., Jonasch, E.,  
 861 Jones, C., Joosten, L.A., Jordan, J., Joseph, A.M., Joseph, B., Joubert, A.M., Ju, D., Ju, J., Juan,  
 862 H.F., Juenemann, K., Juhasz, G., Jung, H.S., Jung, J.U., Jung, Y.K., Jungbluth, H., Justice, M.J.,  
 863 Jutten, B., Kaakoush, N.O., Kaarniranta, K., Kaasik, A., Kabuta, T., Kaeffer, B., Kagedal, K.,  
 864 Kahana, A., Kajimura, S., Kakhlon, O., Kalia, M., Kalvakolanu, D.V., Kamada, Y., Kambas, K.,  
 865 Kaminsky, V.O., Kampinga, H.H., Kandouz, M., Kang, C., Kang, R., Kang, T.C., Kanki, T.,  
 866 Kanneganti, T.D., Kanno, H., Kanthasamy, A.G., Kantorow, M., Kaparakis-Liaskos, M., Kapuy,  
 867 O., Karantza, V., Karim, M.R., Karmakar, P., Kaser, A., Kaushik, S., Kawula, T., Kaynar, A.M.,  
 868 Ke, P.Y., Ke, Z.J., Kehrl, J.H., Keller, K.E., Kemper, J.K., Kenworthy, A.K., Kepp, O., Kern, A.,  
 869 Kesari, S., Kessel, D., Ketteler, R., Kettelhut, Ido, C., Khambu, B., Khan, M.M., Khandelwal,  
 870 V.K., Khare, S., Kiang, J.G., Kiger, A.A., Kihara, A., Kim, A.L., Kim, C.H., Kim, D.R., Kim,  
 871 D.H., Kim, E.K., Kim, H.Y., Kim, H.R., Kim, J.S., Kim, J.H., Kim, J.C., Kim, J.H., Kim, K.W.,  
 872 Kim, M.D., Kim, M.M., Kim, P.K., Kim, S.W., Kim, S.Y., Kim, Y.S., Kim, Y., Kimchi, A.,  
 873 Kimmelman, A.C., Kimura, T., King, J.S., Kirkegaard, K., Kirkin, V., Kirshenbaum, L.A., Kishi,

874 S., Kitajima, Y., Kitamoto, K., Kitaoka, Y., Kitazato, K., Kley, R.A., Klimecki, W.T.,  
 875 Klinkenberg, M., Klucken, J., Knaevelsrud, H., Knecht, E., Knuppertz, L., Ko, J.L., Kobayashi,  
 876 S., Koch, J.C., Koechlin-Ramonatxo, C., Koenig, U., Koh, Y.H., Kohler, K., Kohlwein, S.D.,  
 877 Koike, M., Komatsu, M., Kominami, E., Kong, D., Kong, H.J., Konstantakou, E.G., Kopp, B.T.,  
 878 Korcsmaros, T., Korhonen, L., Korolchuk, V.I., Koshkina, N.V., Kou, Y., Koukourakis, M.I.,  
 879 Koumenis, C., Kovacs, A.L., Kovacs, T., Kovacs, W.J., Koya, D., Kraft, C., Krainc, D., Kramer,  
 880 H., Kravic-Stevovic, T., Krek, W., Kretz-Remy, C., Krick, R., Krishnamurthy, M., Kriston-Vizi,  
 881 J., Kroemer, G., Kruer, M.C., Kruger, R., Ktistakis, N.T., Kuchitsu, K., Kuhn, C., Kumar, A.P.,  
 882 Kumar, A., Kumar, A., Kumar, D., Kumar, D., Kumar, R., Kumar, S., Kundu, M., Kung, H.J.,  
 883 Kuno, A., Kuo, S.H., Kuret, J., Kurz, T., Kwok, T., Kwon, T.K., Kwon, Y.T., Kymizi, I., La  
 884 Spada, A.R., Lafont, F., Lahm, T., Lakkaraju, A., Lam, T., Lamark, T., Lancel, S., Landowski,  
 885 T.H., Lane, D.J., Lane, J.D., Lanzi, C., Lapaquette, P., Lapierre, L.R., Laporte, J., Laukkanen,  
 886 J., Laurie, G.W., Lavandero, S., Lavie, L., LaVoie, M.J., Law, B.Y., Law, H.K., Law, K.B.,  
 887 Layfield, R., Lazo, P.A., Le Cam, L., Le Roch, K.G., Le Stunff, H., Leardkamolkarn, V., Lecuit,  
 888 M., Lee, B.H., Lee, C.H., Lee, E.F., Lee, G.M., Lee, H.J., Lee, H., Lee, J.K., Lee, J., Lee, J.H.,  
 889 Lee, J.H., Lee, M., Lee, M.S., Lee, P.J., Lee, S.W., Lee, S.J., Lee, S.J., Lee, S.Y., Lee, S.H., Lee,  
 890 S.S., Lee, S.J., Lee, S., Lee, Y.R., Lee, Y.J., Lee, Y.H., Leeuwenburgh, C., Lefort, S., Legouis,  
 891 R., Lei, J., Lei, Q.Y., Leib, D.A., Leibowitz, G., Lekli, I., Lemaire, S.D., Lemasters, J.J.,  
 892 Lemberg, M.K., Lemoine, A., Leng, S., Lenz, G., Lenzi, P., Lerman, L.O., Lettieri Barbato, D.,  
 893 Leu, J.I., Leung, H.Y., Levine, B., Lewis, P.A., Lezoualc'h, F., Li, C., Li, F., Li, F.J., Li, J., Li,  
 894 K., Li, L., Li, M., Li, M., Li, Q., Li, R., Li, S., Li, W., Li, W., Li, X., Li, Y., Lian, J., Liang, C.,  
 895 Liang, Q., Liao, Y., Liberal, J., Liberski, P.P., Lie, P., Lieberman, A.P., Lim, H.J., Lim, K.L.,  
 896 Lim, K., Lima, R.T., Lin, C.S., Lin, C.F., Lin, F., Lin, F., Lin, F.C., Lin, K., Lin, K.H., Lin, P.H.,

897 Lin, T., Lin, W.W., Lin, Y.S., Lin, Y., Linden, R., Lindholm, D., Lindqvist, L.M., Lingor, P.,  
 898 Linkermann, A., Liotta, L.A., Lipinski, M.M., Lira, V.A., Lisanti, M.P., Liton, P.B., Liu, B., Liu,  
 899 C., Liu, C.F., Liu, F., Liu, H.J., Liu, J., Liu, J.J., Liu, J.L., Liu, K., Liu, L., Liu, L., Liu, Q., Liu,  
 900 R.Y., Liu, S., Liu, S., Liu, W., Liu, X.D., Liu, X., Liu, X.H., Liu, X., Liu, X., Liu, X., Liu, Y.,  
 901 Liu, Y., Liu, Z., Liu, Z., Liuzzi, J.P., Lizard, G., Ljubic, M., Lodhi, I.J., Logue, S.E., Lokeshwar,  
 902 B.L., Long, Y.C., Lonial, S., Loos, B., Lopez-Otin, C., Lopez-Vicario, C., Lorente, M., Lorenzi,  
 903 P.L., Lorincz, P., Los, M., Lotze, M.T., Lovat, P.E., Lu, B., Lu, B., Lu, J., Lu, Q., Lu, S.M., Lu,  
 904 S., Lu, Y., Luciano, F., Luckhart, S., Lucocq, J.M., Ludovico, P., Lugea, A., Lukacs, N.W., Lum,  
 905 J.J., Lund, A.H., Luo, H., Luo, J., Luo, S., Luparello, C., Lyons, T., Ma, J., Ma, Y., Ma, Y., Ma,  
 906 Z., Machado, J., Machado-Santelli, G.M., Macian, F., MacIntosh, G.C., MacKeigan, J.P.,  
 907 Macleod, K.F., MacMicking, J.D., MacMillan-Crow, L.A., Madeo, F., Madesh, M., Madrigal-  
 908 Matute, J., Maeda, A., Maeda, T., Maegawa, G., Maellaro, E., Maes, H., Magarinos, M., Maiese,  
 909 K., Maiti, T.K., Maiuri, L., Maiuri, M.C., Maki, C.G., Malli, R., Malorni, W., Maloyan, A.,  
 910 Mami-Chouaib, F., Man, N., Mancias, J.D., Mandelkow, E.M., Mandell, M.A., Manfredi, A.A.,  
 911 Manie, S.N., Manzoni, C., Mao, K., Mao, Z., Mao, Z.W., Marambaud, P., Marconi, A.M.,  
 912 Marelja, Z., Marfe, G., Margeta, M., Margittai, E., Mari, M., Mariani, F.V., Marin, C., Marinelli,  
 913 S., Marino, G., Markovic, I., Marquez, R., Martelli, A.M., Martens, S., Martin, K.R., Martin,  
 914 S.J., Martin, S., Martin-Acebes, M.A., Martin-Sanz, P., Martinand-Mari, C., Martinet, W.,  
 915 Martinez, J., Martinez-Lopez, N., Martinez-Outschoorn, U., Martinez-Velazquez, M., Martinez-  
 916 Vicente, M., Martins, W.K., Mashima, H., Mastrianni, J.A., Matarese, G., Matarrese, P., Mateo,  
 917 R., Matoba, S., Matsumoto, N., Matsushita, T., Matsuura, A., Matsuzawa, T., Mattson, M.P.,  
 918 Matus, S., Maugeri, N., Mauvezin, C., Mayer, A., Maysinger, D., Mazzolini, G.D., McBrayer,  
 919 M.K., McCall, K., McCormick, C., McInerney, G.M., McIver, S.C., McKenna, S., McMahon,

920 J.J., McNeish, I.A., Mechta-Grigoriou, F., Medema, J.P., Medina, D.L., Megyeri, K., Mehrpour,  
 921 M., Mehta, J.L., Mei, Y., Meier, U.C., Meijer, A.J., Melendez, A., Melino, G., Melino, S., de  
 922 Melo, E.J., Mena, M.A., Meneghini, M.D., Menendez, J.A., Menezes, R., Meng, L., Meng, L.H.,  
 923 Meng, S., Menghini, R., Menko, A.S., Menna-Barreto, R.F., Menon, M.B., Meraz-Rios, M.A.,  
 924 Merla, G., Merlini, L., Merlot, A.M., Meryk, A., Meschini, S., Meyer, J.N., Mi, M.T., Miao,  
 925 C.Y., Micale, L., Michaeli, S., Michiels, C., Migliaccio, A.R., Mihailidou, A.S., Mijaljica, D.,  
 926 Mikoshiba, K., Milan, E., Miller-Fleming, L., Mills, G.B., Mills, I.G., Minakaki, G., Minassian,  
 927 B.A., Ming, X.F., Minibayeva, F., Minina, E.A., Mintern, J.D., Minucci, S., Miranda-Vizueté,  
 928 A., Mitchell, C.H., Miyamoto, S., Miyazawa, K., Mizushima, N., Mnich, K., Mograbi, B.,  
 929 Mohseni, S., Moita, L.F., Molinari, M., Molinari, M., Moller, A.B., Mollereau, B., Mollinedo, F.,  
 930 Mongillo, M., Monick, M.M., Montagnaro, S., Montell, C., Moore, D.J., Moore, M.N., Mora-  
 931 Rodriguez, R., Moreira, P.I., Morel, E., Morelli, M.B., Moreno, S., Morgan, M.J., Moris, A.,  
 932 Moriyasu, Y., Morrison, J.L., Morrison, L.A., Morselli, E., Moscat, J., Moseley, P.L., Mostowý,  
 933 S., Motori, E., Mottet, D., Mottram, J.C., Moussa, C.E., Mpakou, V.E., Mukhtar, H., Mulcahy  
 934 Levy, J.M., Muller, S., Munoz-Moreno, R., Munoz-Pinedo, C., Munz, C., Murphy, M.E.,  
 935 Murray, J.T., Murthy, A., Mysorekar, I.U., Nabi, I.R., Nabissi, M., Nader, G.A., Nagahara, Y.,  
 936 Nagai, Y., Nagata, K., Nagelkerke, A., Nagy, P., Naidu, S.R., Nair, S., Nakano, H., Nakatogawa,  
 937 H., Nanjundan, M., Napolitano, G., Naqvi, N.I., Nardacci, R., Narendra, D.P., Narita, M.,  
 938 Nascimbeni, A.C., Natarajan, R., Navegantes, L.C., Nawrocki, S.T., Nazarko, T.Y., Nazarko,  
 939 V.Y., Neill, T., Neri, L.M., Netea, M.G., Netea-Maier, R.T., Neves, B.M., Ney, P.A., Nezis, I.P.,  
 940 Nguyen, H.T., Nguyen, H.P., Nicot, A.S., Nilsen, H., Nilsson, P., Nishimura, M., Nishino, I.,  
 941 Niso-Santano, M., Niu, H., Nixon, R.A., Njar, V.C., Noda, T., Noegel, A.A., Nolte, E.M.,  
 942 Norberg, E., Norga, K.K., Noureini, S.K., Notomi, S., Notterpek, L., Nowikovsky, K., Nukina,

943 N., Nurnberger, T., O'Donnell, V.B., O'Donovan, T., O'Dwyer, P.J., Oehme, I., Oeste, C.L.,  
 944 Ogawa, M., Ogretmen, B., Ogura, Y., Oh, Y.J., Ohmuraya, M., Ohshima, T., Ojha, R., Okamoto,  
 945 K., Okazaki, T., Oliver, F.J., Ollinger, K., Olsson, S., Orban, D.P., Ordonez, P., Orhon, I., Orosz,  
 946 L., O'Rourke, E.J., Orozco, H., Ortega, A.L., Ortona, E., Osellame, L.D., Oshima, J., Oshima, S.,  
 947 Osiewacz, H.D., Otomo, T., Otsu, K., Ou, J.H., Outeiro, T.F., Ouyang, D.Y., Ouyang, H.,  
 948 Overholtzer, M., Ozbun, M.A., Ozdinler, P.H., Ozpolat, B., Pacelli, C., Paganetti, P., Page, G.,  
 949 Pages, G., Pagnini, U., Pajak, B., Pak, S.C., Pakos-Zebrucka, K., Pakpour, N., Palkova, Z.,  
 950 Palladino, F., Pallauf, K., Pallet, N., Palmieri, M., Paludan, S.R., Palumbo, C., Palumbo, S.,  
 951 Pampliega, O., Pan, H., Pan, W., Panaretakis, T., Pandey, A., Pantazopoulou, A., Papackova, Z.,  
 952 Papademetrio, D.L., Papassideri, I., Papini, A., Parajuli, N., Pardo, J., Parekh, V.V., Parenti, G.,  
 953 Park, J.I., Park, J., Park, O.K., Parker, R., Parlato, R., Parys, J.B., Parzych, K.R., Pasquet, J.M.,  
 954 Pasquier, B., Pasumarthi, K.B., Patschan, D., Patterson, C., Pattingre, S., Pattison, S., Pause, A.,  
 955 Pavenstadt, H., Pavone, F., Pedrozo, Z., Pena, F.J., Penalva, M.A., Pende, M., Peng, J., Penna,  
 956 F., Penninger, J.M., Pensalfini, A., Pepe, S., Pereira, G.J., Pereira, P.C., Perez-de la Cruz, V.,  
 957 Perez-Perez, M.E., Perez-Rodriguez, D., Perez-Sala, D., Perier, C., Perl, A., Perlmutter, D.H.,  
 958 Perrotta, I., Pervaiz, S., Pesonen, M., Pessin, J.E., Peters, G.J., Petersen, M., Petrache, I., Petrof,  
 959 B.J., Petrovski, G., Phang, J.M., Piacentini, M., Pierdominici, M., Pierre, P., Pierrefite-Carle, V.,  
 960 Pietrocola, F., Pimentel-Muinos, F.X., Pinar, M., Pineda, B., Pinkas-Kramarski, R., Pinti, M.,  
 961 Pinton, P., Piperdi, B., Piret, J.M., Plataniias, L.C., Platta, H.W., Plowey, E.D., Poggeler, S.,  
 962 Poirrot, M., Polcic, P., Poletti, A., Poon, A.H., Popelka, H., Popova, B., Poprawa, I., Poulouse,  
 963 S.M., Poulton, J., Powers, S.K., Powers, T., Pozuelo-Rubio, M., Prak, K., Prange, R., Prescott,  
 964 M., Priault, M., Prince, S., Proia, R.L., Proikas-Cezanne, T., Prokisch, H., Promponas, V.J.,  
 965 Przyklenk, K., Puertollano, R., Pugazhenth, S., Puglielli, L., Pujol, A., Puyal, J., Pyeon, D., Qi,

966 X., Qian, W.B., Qin, Z.H., Qiu, Y., Qu, Z., Quadrilatero, J., Quinn, F., Raben, N., Rabinowich,  
 967 H., Radogna, F., Ragusa, M.J., Rahmani, M., Raina, K., Ramanadham, S., Ramesh, R., Rami, A.,  
 968 Randall-Demllo, S., Randow, F., Rao, H., Rao, V.A., Rasmussen, B.B., Rasse, T.M., Ratovitski,  
 969 E.A., Rautou, P.E., Ray, S.K., Razani, B., Reed, B.H., Reggiori, F., Rehm, M., Reichert, A.S.,  
 970 Rein, T., Reiner, D.J., Reits, E., Ren, J., Ren, X., Renna, M., Reusch, J.E., Revuelta, J.L., Reyes,  
 971 L., Rezaie, A.R., Richards, R.I., Richardson, D.R., Richetta, C., Riehle, M.A., Rihn, B.H.,  
 972 Rikihisa, Y., Riley, B.E., Rimbach, G., Rippo, M.R., Ritis, K., Rizzi, F., Rizzo, E., Roach, P.J.,  
 973 Robbins, J., Roberge, M., Roca, G., Roccheri, M.C., Rocha, S., Rodrigues, C.M., Rodriguez,  
 974 C.I., de Cordoba, S.R., Rodriguez-Muela, N., Roelofs, J., Rogov, V.V., Rohn, T.T., Rohrer, B.,  
 975 Romanelli, D., Romani, L., Romano, P.S., Roncero, M.I., Rosa, J.L., Rosello, A., Rosen, K.V.,  
 976 Rosenstiel, P., Rost-Roszkowska, M., Roth, K.A., Roue, G., Rouis, M., Rouschop, K.M., Ruan,  
 977 D.T., Ruano, D., Rubinsztejn, D.C., Rucker, E.B., 3rd, Rudich, A., Rudolf, E., Rudolf, R.,  
 978 Ruegg, M.A., Ruiz-Roldan, C., Ruparelia, A.A., Rusmini, P., Russ, D.W., Russo, G.L., Russo,  
 979 G., Russo, R., Rusten, T.E., Ryabovol, V., Ryan, K.M., Ryter, S.W., Sabatini, D.M., Sacher, M.,  
 980 Sachse, C., Sack, M.N., Sadoshima, J., Saftig, P., Sagi-Eisenberg, R., Sahni, S., Saikumar, P.,  
 981 Saito, T., Saitoh, T., Sakakura, K., Sakoh-Nakatogawa, M., Sakuraba, Y., Salazar-Roa, M.,  
 982 Salomoni, P., Saluja, A.K., Salvaterra, P.M., Salvioli, R., Samali, A., Sanchez, A.M., Sanchez-  
 983 Alcazar, J.A., Sanchez-Prieto, R., Sandri, M., Sanjuan, M.A., Santaguida, S., Santambrogio, L.,  
 984 Santoni, G., Dos Santos, C.N., Saran, S., Sardiello, M., Sargent, G., Sarkar, P., Sarkar, S.,  
 985 Sarrias, M.R., Sarwal, M.M., Sasakawa, C., Sasaki, M., Sass, M., Sato, K., Sato, M., Satriano, J.,  
 986 Savaraj, N., Saveljeva, S., Schaefer, L., Schaible, U.E., Scharl, M., Schatzl, H.M., Schekman, R.,  
 987 Scheper, W., Schiavi, A., Schipper, H.M., Schmeisser, H., Schmidt, J., Schmitz, I., Schneider,  
 988 B.E., Schneider, E.M., Schneider, J.L., Schon, E.A., Schonenberger, M.J., Schonthal, A.H.,

989 Schorderet, D.F., Schroder, B., Schuck, S., Schulze, R.J., Schwarten, M., Schwarz, T.L.,  
 990 Sciarretta, S., Scotto, K., Scovassi, A.I., Screatton, R.A., Screen, M., Seca, H., Sedej, S., Segatori,  
 991 L., Segev, N., Seglen, P.O., Segui-Simarro, J.M., Segura-Aguilar, J., Seki, E., Sell, C., Seiliez, I.,  
 992 Semenkovich, C.F., Semenza, G.L., Sen, U., Serra, A.L., Serrano-Puebla, A., Sesaki, H.,  
 993 Setoguchi, T., Settembre, C., Shacka, J.J., Shajahan-Haq, A.N., Shapiro, I.M., Sharma, S., She,  
 994 H., Shen, C.K., Shen, C.C., Shen, H.M., Shen, S., Shen, W., Sheng, R., Sheng, X., Sheng, Z.H.,  
 995 Shepherd, T.G., Shi, J., Shi, Q., Shi, Q., Shi, Y., Shibutani, S., Shibuya, K., Shidoji, Y., Shieh,  
 996 J.J., Shih, C.M., Shimada, Y., Shimizu, S., Shin, D.W., Shinohara, M.L., Shintani, M., Shintani,  
 997 T., Shioi, T., Shirabe, K., Shiri-Sverdlov, R., Shirihai, O., Shore, G.C., Shu, C.W., Shukla, D.,  
 998 Sibirny, A.A., Sica, V., Sigurdson, C.J., Sigurdsson, E.M., Sijwali, P.S., Sikorska, B., Silveira,  
 999 W.A., Silvente-Poirot, S., Silverman, G.A., Simak, J., Simmet, T., Simon, A.K., Simon, H.U.,  
 1000 Simone, C., Simons, M., Simonsen, A., Singh, R., Singh, S.V., Singh, S.K., Sinha, D., Sinha, S.,  
 1001 Sinicrope, F.A., Sirko, A., Sirohi, K., Sishi, B.J., Sittler, A., Siu, P.M., Sivridis, E., Skwarska,  
 1002 A., Slack, R., Slaninova, I., Slavov, N., Smaili, S.S., Smalley, K.S., Smith, D.R., Soenen, S.J.,  
 1003 Soleimanpour, S.A., Solhaug, A., Somasundaram, K., Son, J.H., Sonawane, A., Song, C., Song,  
 1004 F., Song, H.K., Song, J.X., Song, W., Soo, K.Y., Sood, A.K., Soong, T.W., Soontornniyomkij,  
 1005 V., Sorice, M., Sotgia, F., Soto-Pantoja, D.R., Sotthibundhu, A., Sousa, M.J., Spaink, H.P., Span,  
 1006 P.N., Spang, A., Sparks, J.D., Speck, P.G., Spector, S.A., Spies, C.D., Springer, W., Clair, D.S.,  
 1007 Stacchiotti, A., Staels, B., Stang, M.T., Starczynowski, D.T., Starokadomskyy, P., Steegborn, C.,  
 1008 Steele, J.W., Stefanis, L., Steffan, J., Stellrecht, C.M., Stenmark, H., Stepkowski, T.M., Stern,  
 1009 S.T., Stevens, C., Stockwell, B.R., Stoka, V., Storchova, Z., Stork, B., Stratoulis, V.,  
 1010 Stravopodis, D.J., Strnad, P., Strohecker, A.M., Strom, A.L., Stromhaug, P., Stulik, J., Su, Y.X.,  
 1011 Su, Z., Subauste, C.S., Subramaniam, S., Sue, C.M., Suh, S.W., Sui, X., Sukserree, S., Sulzer, D.,

1012 Sun, F.L., Sun, J., Sun, J., Sun, S.Y., Sun, Y., Sun, Y., Sun, Y., Sundaramoorthy, V., Sung, J.,  
 1013 Suzuki, H., Suzuki, K., Suzuki, N., Suzuki, T., Suzuki, Y.J., Swanson, M.S., Swanton, C.,  
 1014 Sward, K., Swarup, G., Sweeney, S.T., Sylvester, P.W., Szatmari, Z., Szegezdi, E., Szlosarek,  
 1015 P.W., Taegtmeier, H., Tafani, M., Taillebourg, E., Tait, S.W., Takacs-Vellai, K., Takahashi, Y.,  
 1016 Takats, S., Takemura, G., Takigawa, N., Talbot, N.J., Tamagno, E., Tamburini, J., Tan, C.P.,  
 1017 Tan, L., Tan, M.L., Tan, M., Tan, Y.J., Tanaka, K., Tanaka, M., Tang, D., Tang, D., Tang, G.,  
 1018 Tanida, I., Tanji, K., Tannous, B.A., Tapia, J.A., Tasset-Cuevas, I., Tatar, M., Tavassoly, I.,  
 1019 Tavernarakis, N., Taylor, A., Taylor, G.S., Taylor, G.A., Taylor, J.P., Taylor, M.J., Tchetina,  
 1020 E.V., Tee, A.R., Teixeira-Clerc, F., Telang, S., Tencomnao, T., Teng, B.B., Teng, R.J., Terro, F.,  
 1021 Tettamanti, G., Theiss, A.L., Theron, A.E., Thomas, K.J., Thome, M.P., Thomes, P.G.,  
 1022 Thorburn, A., Thorner, J., Thum, T., Thumm, M., Thurston, T.L., Tian, L., Till, A., Ting, J.P.,  
 1023 Titorenko, V.I., Toker, L., Toldo, S., Tooze, S.A., Topisirovic, I., Torgersen, M.L., Torosantucci,  
 1024 L., Torriglia, A., Torrisi, M.R., Tournier, C., Towns, R., Trajkovic, V., Travassos, L.H., Triola,  
 1025 G., Tripathi, D.N., Trisciuglio, D., Troncoso, R., Trougakos, I.P., Truttmann, A.C., Tsai, K.J.,  
 1026 Tschan, M.P., Tseng, Y.H., Tsukuba, T., Tsung, A., Tsvetkov, A.S., Tu, S., Tuan, H.Y., Tucci,  
 1027 M., Tumbarello, D.A., Turk, B., Turk, V., Turner, R.F., Tveita, A.A., Tyagi, S.C., Ubukata, M.,  
 1028 Uchiyama, Y., Udelnow, A., Ueno, T., Umekawa, M., Umemiya-Shirafuji, R., Underwood, B.R.,  
 1029 Ungermann, C., Ureshino, R.P., Ushioda, R., Uversky, V.N., Uzcategui, N.L., Vaccari, T.,  
 1030 Vaccaro, M.I., Vachova, L., Vakifahmetoglu-Norberg, H., Valdor, R., Valente, E.M., Vallette,  
 1031 F., Valverde, A.M., Van den Berghe, G., Van Den Bosch, L., van den Brink, G.R., van der Goot,  
 1032 F.G., van der Klei, I.J., van der Laan, L.J., van Doorn, W.G., van Egmond, M., van Golen, K.L.,  
 1033 Van Kaer, L., van Lookeren Campagne, M., Vandenabeele, P., Vandenbergh, W., Vanhorebeek,  
 1034 I., Varela-Nieto, I., Vasconcelos, M.H., Vasko, R., Vavvas, D.G., Vega-Naredo, I., Velasco, G.,



1035 Velentzas, A.D., Velentzas, P.D., Vellai, T., Vellenga, E., Vendelbo, M.H., Venkatachalam, K.,  
 1036 Ventura, N., Ventura, S., Veras, P.S., Verdier, M., Vertessy, B.G., Viale, A., Vidal, M., Vieira,  
 1037 H.L., Vierstra, R.D., Vigneswaran, N., Vij, N., Vila, M., Villar, M., Villar, V.H., Villarroja, J.,  
 1038 Vindis, C., Viola, G., Viscomi, M.T., Vitale, G., Vogl, D.T., Voitsekhovskaja, O.V., von Haefen,  
 1039 C., von Schwarzenberg, K., Voth, D.E., Vouret-Craviari, V., Vuori, K., Vyas, J.M., Waeber, C.,  
 1040 Walker, C.L., Walker, M.J., Walter, J., Wan, L., Wan, X., Wang, B., Wang, C., Wang, C.Y.,  
 1041 Wang, C., Wang, C., Wang, C., Wang, D., Wang, F., Wang, F., Wang, G., Wang, H.J., Wang,  
 1042 H., Wang, H.G., Wang, H., Wang, H.D., Wang, J., Wang, J., Wang, M., Wang, M.Q., Wang,  
 1043 P.Y., Wang, P., Wang, R.C., Wang, S., Wang, T.F., Wang, X., Wang, X.J., Wang, X.W., Wang,  
 1044 X., Wang, X., Wang, Y., Wang, Y., Wang, Y., Wang, Y.J., Wang, Y., Wang, Y., Wang, Y.T.,  
 1045 Wang, Y., Wang, Z.N., Wappner, P., Ward, C., Ward, D.M., Warnes, G., Watada, H., Watanabe,  
 1046 Y., Watase, K., Weaver, T.E., Weekes, C.D., Wei, J., Weide, T., Weihl, C.C., Weindl, G., Weis,  
 1047 S.N., Wen, L., Wen, X., Wen, Y., Westermann, B., Weyand, C.M., White, A.R., White, E.,  
 1048 Whitton, J.L., Whitworth, A.J., Wiels, J., Wild, F., Wildenberg, M.E., Wileman, T., Wilkinson,  
 1049 D.S., Wilkinson, S., Willbold, D., Williams, C., Williams, K., Williamson, P.R., Winklhofer,  
 1050 K.F., Witkin, S.S., Wohlgemuth, S.E., Wollert, T., Wolvetang, E.J., Wong, E., Wong, G.W.,  
 1051 Wong, R.W., Wong, V.K., Woodcock, E.A., Wright, K.L., Wu, C., Wu, D., Wu, G.S., Wu, J.,  
 1052 Wu, J., Wu, M., Wu, M., Wu, S., Wu, W.K., Wu, Y., Wu, Z., Xavier, C.P., Xavier, R.J., Xia,  
 1053 G.X., Xia, T., Xia, W., Xia, Y., Xiao, H., Xiao, J., Xiao, S., Xiao, W., Xie, C.M., Xie, Z., Xie,  
 1054 Z., Xilouri, M., Xiong, Y., Xu, C., Xu, C., Xu, F., Xu, H., Xu, H., Xu, J., Xu, J., Xu, J., Xu, L.,  
 1055 Xu, X., Xu, Y., Xu, Y., Xu, Z.X., Xu, Z., Xue, Y., Yamada, T., Yamamoto, A., Yamanaka, K.,  
 1056 Yamashina, S., Yamashiro, S., Yan, B., Yan, B., Yan, X., Yan, Z., Yanagi, Y., Yang, D.S.,  
 1057 Yang, J.M., Yang, L., Yang, M., Yang, P.M., Yang, P., Yang, Q., Yang, W., Yang, W.Y., Yang,

1058 X., Yang, Y., Yang, Y., Yang, Z., Yang, Z., Yao, M.C., Yao, P.J., Yao, X., Yao, Z., Yao, Z.,  
 1059 Yasui, L.S., Ye, M., Yedvobnick, B., Yeganeh, B., Yeh, E.S., Yeyati, P.L., Yi, F., Yi, L., Yin,  
 1060 X.M., Yip, C.K., Yoo, Y.M., Yoo, Y.H., Yoon, S.Y., Yoshida, K., Yoshimori, T., Young, K.H.,  
 1061 Yu, H., Yu, J.J., Yu, J.T., Yu, J., Yu, L., Yu, W.H., Yu, X.F., Yu, Z., Yuan, J., Yuan, Z.M., Yue,  
 1062 B.Y., Yue, J., Yue, Z., Zacks, D.N., Zacksenhaus, E., Zaffaroni, N., Zaglia, T., Zakeri, Z.,  
 1063 Zecchini, V., Zeng, J., Zeng, M., Zeng, Q., Zervos, A.S., Zhang, D.D., Zhang, F., Zhang, G.,  
 1064 Zhang, G.C., Zhang, H., Zhang, H., Zhang, H., Zhang, H., Zhang, J., Zhang, J., Zhang, J., Zhang,  
 1065 J., Zhang, J.P., Zhang, L., Zhang, L., Zhang, L., Zhang, L., Zhang, M.Y., Zhang, X., Zhang,  
 1066 X.D., Zhang, Y., Zhang, Y., Zhang, Y., Zhang, Y., Zhang, Y., Zhao, M., Zhao, W.L., Zhao, X.,  
 1067 Zhao, Y.G., Zhao, Y., Zhao, Y., Zhao, Y.X., Zhao, Z., Zhao, Z.J., Zheng, D., Zheng, X.L.,  
 1068 Zheng, X., Zhivotovsky, B., Zhong, Q., Zhou, G.Z., Zhou, G., Zhou, H., Zhou, S.F., Zhou, X.J.,  
 1069 Zhu, H., Zhu, H., Zhu, W.G., Zhu, W., Zhu, X.F., Zhu, Y., Zhuang, S.M., Zhuang, X., Ziparo,  
 1070 E., Zois, C.E., Zoladek, T., Zong, W.X., Zorzano, A., Zughaier, S.M., 2016. Guidelines for the  
 1071 use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 12, 1-222.  
 1072 Kobayashi, M., Otsuka, Y., Itagaki, S., Hirano, T., Iseki, K., 2006. Inhibitory effects of statins on  
 1073 human monocarboxylate transporter 4. *International journal of pharmaceutics* 317, 19-25.  
 1074 Kobayashi, Y., Kashima, H., Rahmanto, Y.S., Banno, K., Yu, Y., Matoba, Y., Watanabe, K.,  
 1075 Iijima, M., Takeda, T., Kunitomi, H., Iida, M., Adachi, M., Nakamura, K., Tsuji, K., Masuda, K.,  
 1076 Nomura, H., Tominaga, E., Aoki, D., 2017. Drug repositioning of mevalonate pathway inhibitors  
 1077 as antitumor agents for ovarian cancer. *Oncotarget* 8, 72147-72156.  
 1078 Kobayashi, Y., Kashima, H., Wu, R.C., Jung, J.G., Kuan, J.C., Gu, J., Xuan, J., Sokoll, L.,  
 1079 Visvanathan, K., Shih Ie, M., Wang, T.L., 2015. Mevalonate Pathway Antagonist Suppresses  
 1080 Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

1081 Clinical cancer research : an official journal of the American Association for Cancer Research  
 1082 21, 4652-4662.

1083 Kwak, H.B., Thalacker-Mercer, A., Anderson, E.J., Lin, C.T., Kane, D.A., Lee, N.S., Cortright,  
 1084 R.N., Bamman, M.M., Neuffer, P.D., 2012. Simvastatin impairs ADP-stimulated respiration and  
 1085 increases mitochondrial oxidative stress in primary human skeletal myotubes. Free radical  
 1086 biology & medicine 52, 198-207.

1087 Levinger, I., Ventura, Y., Vago, R., 2014. Life is three dimensional-as in vitro cancer cultures  
 1088 should be. Advances in cancer research 121, 383-414.

1089 Liu, G., Pei, F., Yang, F., Li, L., Amin, A.D., Liu, S., Buchan, J.R., Cho, W.C., 2017. Role of  
 1090 Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci 18.

1091 Ma, X.H., Piao, S., Wang, D., McAfee, Q.W., Nathanson, K.L., Lum, J.J., Li, L.Z., Amaravadi,  
 1092 R.K., 2011. Measurements of tumor cell autophagy predict invasiveness, resistance to  
 1093 chemotherapy, and survival in melanoma. Clinical cancer research : an official journal of the  
 1094 American Association for Cancer Research 17, 3478-3489.

1095 Matzno, S., Yamauchi, T., Gohda, M., Ishida, N., Katsuura, K., Hanasaki, Y., Tokunaga, T.,  
 1096 Itoh, H., Nakamura, N., 1997. Inhibition of cholesterol biosynthesis by squalene epoxidase  
 1097 inhibitor avoids apoptotic cell death in L6 myoblasts. J Lipid Res 38, 1639-1648.

1098 Mehrbod, P., Ande, S.R., Alizadeh, J., Rahimizadeh, S., Shariati, A., Malek, H., Hashemi, M.,  
 1099 Glover, K.K.M., Sher, A.A., Coombs, K.M., Ghavami, S., 2019. The roles of apoptosis,  
 1100 autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections.  
 1101 Virulence 10, 376-413.

1102 Mizushima, N., Yoshimori, T., Levine, B., 2010. Methods in mammalian autophagy research.  
 1103 Cell 140, 313-326.

1104 Moghadam, A.R., da Silva Rosa, S.C., Samiei, E., Alizadeh, J., Field, J., Kawalec, P., Thliveris,  
 1105 J., Akbari, M., Ghavami, S., Gordon, J.W., 2018. Autophagy modulates temozolomide-induced  
 1106 cell death in alveolar Rhabdomyosarcoma cells. *Cell Death Discov* 4, 52.

1107 Mokarram, P., Albokashy, M., Zarghooni, M., Moosavi, M.A., Sepehri, Z., Chen, Q.M.,  
 1108 Hudecki, A., Sargazi, A., Alizadeh, J., Moghadam, A.R., Hashemi, M., Movassagh, H.,  
 1109 Klonisch, T., Owji, A.A., Los, M.J., Ghavami, S., 2017. New frontiers in the treatment of  
 1110 colorectal cancer: Autophagy and the unfolded protein response as promising targets. *Autophagy*  
 1111 13, 781-819.

1112 Mullen, P.J., Luscher, B., Scharnagl, H., Krahenbuhl, S., Brecht, K., 2010. Effect of simvastatin  
 1113 on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-  
 1114 induced myopathy. *Biochemical pharmacology* 79, 1200-1209.

1115 Pankiv, S., Clausen, T.H., Lamark, T., Brech, A., Bruun, J.A., Outzen, H., Overvatn, A.,  
 1116 Bjorkoy, G., Johansen, T., 2007. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate  
 1117 degradation of ubiquitinated protein aggregates by autophagy. *The Journal of biological*  
 1118 *chemistry* 282, 24131-24145.

1119 Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., Lin, J.H., 2002. Effects of  
 1120 fibrates on metabolism of statins in human hepatocytes. *Drug metabolism and disposition: the*  
 1121 *biological fate of chemicals* 30, 1280-1287.

1122 Sakamoto, K., Honda, T., Yokoya, S., Waguri, S., Kimura, J., 2007. Rab-small GTPases are  
 1123 involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. *FASEB*  
 1124 *journal : official publication of the Federation of American Societies for Experimental Biology*  
 1125 21, 4087-4094.

1126 Schirris, T.J., Renkema, G.H., Ritschel, T., Voermans, N.C., Bilos, A., van Engelen, B.G.,  
 1127 Brandt, U., Koopman, W.J., Beyrath, J.D., Rodenburg, R.J., Willems, P.H., Smeitink, J.A.,  
 1128 Russel, F.G., 2015a. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III  
 1129 Inhibition. *Cell Metab* 22, 399-407.  
 1130 Schirris, T.J., Ritschel, T., Herma Renkema, G., Willems, P.H., Smeitink, J.A., Russel, F.G.,  
 1131 2015b. Mitochondrial ADP/ATP exchange inhibition: a novel off-target mechanism underlying  
 1132 ibipinabant-induced myotoxicity. *Scientific reports* 5, 14533.  
 1133 Seyfoori, A., Samiei, E., Jalili, N., Godau, B., Rahmanian, M., Farahmand, L., Majidzadeh,  
 1134 A.K., Akbari, M., 2018. Self-filling microwell arrays (SFMA) for tumor spheroid formation.  
 1135 *Lab Chip* 18, 3516-3528.  
 1136 Sheikholeslami, K., Ali Sher, A., Lockman, S., Kroft, D., Ganjibakhsh, M., Nejati-Koshki, K.,  
 1137 Shojaei, S., Ghavami, S., Rastegar, M., 2019. Simvastatin Induces Apoptosis in  
 1138 Medulloblastoma Brain Tumor Cells via Mevalonate Cascade Prenylation Substrates. *Cancers*  
 1139 (Basel) 11.  
 1140 Siddals, K.W., Marshman, E., Westwood, M., Gibson, J.M., 2004. Abrogation of insulin-like  
 1141 growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein  
 1142 prenylation and receptor glycosylation pathways. *The Journal of biological chemistry* 279,  
 1143 38353-38359.  
 1144 Sirvent, P., Fabre, O., Bordenave, S., Hillaire-Buys, D., Raynaud De Mauverger, E.,  
 1145 Lacampagne, A., Mercier, J., 2012. Muscle mitochondrial metabolism and calcium signaling  
 1146 impairment in patients treated with statins. *Toxicology and applied pharmacology* 259, 263-268.  
 1147 Song, S., Tan, J., Miao, Y., Li, M., Zhang, Q., 2017. Crosstalk of autophagy and apoptosis:  
 1148 Involvement of the dual role of autophagy under ER stress. *J Cell Physiol* 232, 2977-2984.

1149 Staffa, J.A., Chang, J., Green, L., 2002. Cerivastatin and reports of fatal rhabdomyolysis. N Engl  
 1150 J Med 346, 539-540.

1151 Takeda, N., Kondo, M., Ito, S., Ito, Y., Shimokata, K., Kume, H., 2006. Role of RhoA  
 1152 inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin.  
 1153 American journal of respiratory cell and molecular biology 35, 722-729.

1154 Thompson, P.D., Clarkson, P., Karas, R.H., 2003. Statin-associated myopathy. Jama 289, 1681-  
 1155 1690.

1156 Tikkanen, M.J., Nikkila, E.A., 1987. Current pharmacologic treatment of elevated serum  
 1157 cholesterol. Circulation 76, 529-533.

1158 Ucar, M., Mjorndal, T., Dahlqvist, R., 2000. HMG-CoA reductase inhibitors and myotoxicity.  
 1159 Drug Saf 22, 441-457.

1160 Vilimanovich, U., Bosnjak, M., Bogdanovic, A., Markovic, I., Isakovic, A., Kravic-Stevovic, T.,  
 1161 Mircic, A., Trajkovic, V., Bumbasirevic, V., 2015. Statin-mediated inhibition of cholesterol  
 1162 synthesis induces cytoprotective autophagy in human leukemic cells. Eur J Pharmacol 765, 415-  
 1163 428.

1164 Whitehead, N.P., 2016. Enhanced autophagy as a potential mechanism for the improved  
 1165 physiological function by simvastatin in muscular dystrophy. Autophagy 12, 705-706.

1166 Yeganeh, B., Wiechec, E., Ande, S.R., Sharma, P., Moghadam, A.R., Post, M., Freed, D.H.,  
 1167 Hashemi, M., Shojaei, S., Zeki, A.A., Ghavami, S., 2014. Targeting the mevalonate cascade as a  
 1168 new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther 143,  
 1169 87-110.

1170